Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management

Ping Jin1†, Jingwen Jiang1†, Li Zhou1†, Zhao Huang1, Edouard C. Nice2, Canhua Huang1* and Li Fu3*

Abstract
Drug resistance represents a major obstacle in cancer management, and the mechanisms underlying stress adaptation of cancer cells in response to therapy-induced hostile environment are largely unknown. As the central organelle for cellular energy supply, mitochondria can rapidly undergo dynamic changes and integrate cellular signaling pathways to provide bioenergetic and biosynthetic flexibility for cancer cells, which contributes to multiple aspects of tumor characteristics, including drug resistance. Therefore, targeting mitochondria for cancer therapy and overcoming drug resistance has attracted increasing attention for various types of cancer. Multiple mitochondrial adaptation processes, including mitochondrial dynamics, mitochondrial metabolism, and mitochondrial apoptotic regulatory machinery, have been demonstrated to be potential targets. However, recent increasing insights into mitochondria have revealed the complexity of mitochondrial structure and functions, the elusive functions of mitochondria in tumor biology, and the targeting inaccessibility of mitochondria, which have posed challenges for the clinical application of mitochondrial-based cancer therapeutic strategies. Therefore, discovery of both novel mitochondria-targeting agents and innovative mitochondria-targeting approaches is urgently required. Here, we review the most recent literature to summarize the molecular mechanisms underlying mitochondrial stress adaptation and their intricate connection with cancer drug resistance. In addition, an overview of the emerging strategies to target mitochondria for effectively overcoming chemoresistance is highlighted, with an emphasis on drug repositioning and mitochondrial drug delivery approaches, which may accelerate the application of mitochondria-targeting compounds for cancer therapy.

Keywords: Cancer drug resistance, Mitochondrial dynamics, Mitochondrial adaptation, Drug repurposing, Mitochondrial-targeted drug delivery, Mitochondrial transplantation

Background
Chemotherapy and targeted therapy are mainstream cancer treatments, but their efficiency is limited by frequent drug resistance and tumor relapse [1–3]. Generally, cancer drug resistance can result from two types of mechanism: intrinsic or acquired causes [4–8]. Intrinsic resistance is due to preexisting resistance-mediating factors prior to any treatment administered, while acquired drug resistance is caused by adaptive responses that confer cancer cell survival in unfavorable environments during drug treatment [9–12]. These adaptive
response mechanisms include reduced uptake of drugs or increased drug efflux, ineffective induction of cell death, and compensatory activation of pro-survival signaling pathways [13–15]. Moreover, it is increasingly recognized that drug resistance can generally arise from a minor resistant subpopulation of cancer cells due to the high incidence of tumor heterogeneity. Recent studies have demonstrated that cancer stem cells (CSCs) are prone to maintain a quiescent state to evade the drug cytotoxicity which contributes to the development of a whole resistance phenotype [16–19].

Cancer cells often reprogram their metabolic pathways to provide energetic and biosynthetic flexibility to survive in hostile conditions when exposed to cancer treatments [20–26]. Metabolic reprogramming is considered as one of the major hallmarks of cancer [27] and has been an area of accelerated research over the last century on the basis of aerobic glycolysis theory proposed by Otto von Warburg, which describes the preference for glycolysis by tumors in the presence of oxygen [28–37]. While numerous studies have well documented the crucial role of metabolic adaptations in supporting cancer progression under endogenous stress such as hypoxia, cancer cells also develop metabolic flexibility to survive in response to exogenous stress including drug administration [28, 38–40]. Chemoresistance caused by glucose metabolic plasticity, for example, is generally mediated by several key glycolytic factors, such as Hexokinase 2 (HK2), glucose transporter 1 (GLUT1), as well as pyruvate kinase isozymes M2 (PKM2) [41–44]. The augmentation of glycolysis results in enhanced secretion of lactate and production of glycolytic intermediates, which activate branching pathways (e.g., pentose phosphate pathway (PPP)) and the stress response machinery to support nucleotide synthesis and redox homeostasis, leading to escape from apoptosis and reduction in drug entry [45, 46]. Correspondingly, targeting the dynamic adaptability of metabolism has obtained considerable effect in improving the efficiency of cancer therapy [47–50].

Mitochondria are one of the most evolutionary conserved intracellular organelles that provide bioenergetic and biosynthetic changes, which accompany tumor progression by taking up substrates from the cytoplasm to drive the electron transport chain (ETC) and respiration, the tricarboxylic acid cycle (TCA cycle), fatty acid oxidation (FAO), and subsequent macromolecule synthesis (Fig. 1) [51–54]. Additionally, mitochondria can rapidly sense and adapt to stress stimulation to ensure cell survival. Advanced studies on cancer metabolism have expanded our understanding of mitochondrial metabolic alterations to support anabolic requirements of cancer cells, which depend largely on the strictly intertwined plasticity of mitochondria (mitochondrial dynamics), including fusion/fission, trafficking/transfer, and inter-organelle communication/retrograde signaling [55]. While participating in the maintenance of cellular homeostasis during tumor progression, these mitochondrial adaptive processes are also pivotal for handling drug-induced stress, which contributes to alterations in mitochondrial metabolism and subsequent drug resistance [56–59]. For example, mitochondrial fission provides an advantage for cisplatin-resistant cells compared with their nonresistant counterpart under hypoxic conditions in ovarian cancer [60, 61]. In melanoma, the increased oxidative phosphorylation (OXPHOS) in resistant subclones is supported by peroxisome proliferator-activated receptorcoactivator-1 (PGC-1α) and is required for buffering oxidative stress [46]. Indeed, mitochondria have received increasing attention as a therapeutic target for cancer therapy, and several agents targeting mitochondrial metabolism are under investigation [62–64]. However, the dynamic alterations and inaccessible characteristics of mitochondria make it a priority to explore novel mitochondria-targeting agents and strategies.

Here, we address the most recent findings regarding mitochondrial dynamics to indicate their functions in cancer drug resistance. An overview of existing mitochondrial agents will be presented, and emerging strategies for effective tumor elimination by targeting mitochondria, including drug repurposing and mitochondrial-targeted drug delivery systems, will be summarized.

**Mitochondrial structure and functions**

Mitochondria are one of the most evolutionary conserved intracellular organelles that consist of the outer mitochondrial membrane (OMM) and a highly folded inner mitochondrial membrane (IMM) [65]. These two membranes are separated by the mitochondrial intermembrane space (IMS) and differ from each other in lipid composition and permeability. Importantly, the IMM invaginates into the mitochondrial matrix to form cristae, the crucial structure for mitochondrial function [66]. To maintain these structures, mitochondria undergo multiple complex processes (including fission and fusion) to dynamically control the function of mitochondria under various stimuli [67].

The primary function of mitochondria is demonstrated as energy supply. During the process of energy production, mitochondria integrate several metabolic pathways, including TCA cycle, FAO, amino acid oxidation, OXPHOS, etc., to provide not only most of the cellular ATP but also intermediate metabolite, supporting multiple physiological functions of the organism [68]. In recent decades, numerous studies have demonstrated that mitochondria also function as a signaling organelle to participate in many physiological processes, such as
Ca\textsuperscript{2+} homeostasis, redox homeostasis, apoptosis regulation, and synthesis of heme and iron–sulfur clusters \cite{69}. Indeed, mitochondria regulate Ca\textsuperscript{2+} homeostasis by exporting Ca\textsuperscript{2+} absorbed from intracellular store or extracellular uptake, which release Ca\textsuperscript{2+} back to the cytosol for regulation of calcium-dependent signaling \cite{70}. In addition, the by-products of electron transfer during mitochondrial respiration result in the generation of reactive oxygen species (ROS), in which complexes I and III play the central role \cite{71}. These physiological ROS together with the reducing equivalents (NADPH, etc.) generated by mitochondrial metabolism maintain the redox homeostasis for normal biological functions \cite{72}. Moreover, mitochondria are tightly associated with apoptosis induction, as the release of cytochrome c, the key event of intrinsic apoptotic pathway, is mediated by the mitochondrial outer membrane permeabilization (MOMP) \cite{73}. Therefore, the above complicated functions of mitochondria require the sophisticated regulation of mitochondrial dynamics for maintaining normal physiological functions of the organism.

Mitochondrial defects caused by various stimuli may lead to various pathologies, including neurodegenerative diseases, aging, and especially cancer. A large number of studies have suggested that mitochondria dysfunction may promote cancer onset and progression mainly through the following crucial mechanisms. First, as mitochondria are the major source of intracellular ROS, adequate levels of reactive species not only enable the accumulation of oncogenic defects of genes but also favor the activation of several oncogenic signaling pathways, which result in aberrant cell proliferation \cite{74}. In addition, metabolic pathways in mitochondria may lead to the abnormal accumulation of specific metabolites, such as α-ketoglutarate (α-KG), pyruvate, fumarate, and succinate, which display significant oncogenic role during cancer initiation and progression \cite{75–78}. Moreover, alterations or functional defects in MOMP are beneficial for survival of tumor cells when facing harsh conditions (such as hypoxic stress, metabolic stress, and therapeutic stress), thereby resisting regulated cell death \cite{79}. During the dissemination and colonization, mitochondria endow

---

**Fig. 1** Mitochondria are energetic and biosynthetic signaling hubs. Mitochondria take up substrates from the cytoplasm to provide bioenergetic and biosynthetic flexibility. The TCA cycle coordinates glycolysis and glutaminolysis to provide blocks necessary for macromolecule (nucleotides, lipids, and amino acids) synthesis. This process produces ATP, NADPH, as well as the electron donors in OXPHOS (NADH and FADH2). The ETC complexes produce the majority of cellular ATP and oxidize NADH and FADH2 to NAD\textsuperscript{+} and FAD, respectively, to allow the oxidative TCA cycle to continuously function, producing metabolites that support macromolecule synthesis. DHODH couples de novo pyrimidine synthesis to donate electrons to mitochondrial ubiquinone (CoQ) during the conversion of dihydroorotate to orotate. Mitochondrial dynamics facilitate maximum survival advantages of cancer cells in response to stress by maintaining mitochondrial metabolism, ion homeostasis such as Ca\textsuperscript{2+} signaling, and redox balance.
metastatic cancer cells with phenotypic and metabolic plasticity for survival in intravascular transit and distant sites [80]. Taken together, the complex structures confer the diverse functions of mitochondria, whose dysfunction may regulate several aspects of cancer onset and progression, indicating a promising therapeutic target.

**Mitochondrial stress adaptation and drug resistance**

Mitochondrial metabolic plasticity contributes to resistance in most types of anticancer therapy, as emphasized above [81, 82]. It is well orchestrated as a prerequisite of maintenance of OXPHOS, balance of ROS for signaling or defense, Ca^{2+} homeostasis, and proper induction of the apoptotic cascade. Mitochondrial dynamics modulate their shape, number, quality, and distribution in response to treatment and allow the maintenance of functional mitochondria (Fig. 2) [83]. Mitochondrial biogenesis and turnover, fusion and fission are universal mitochondrial stress-adaptive processes and have been well demonstrated to be involved in cancer drug resistance. Recent advances have expanded the paradigm of mitochondrial dynamics into mitochondrial trafficking and transfer, mitochondrial interplay with other organelles, and mitochondrial retrograde signaling [55, 84, 85]. These processes provide mitochondria plasticity for tumor cells, enabling tumor cells to survive under stress conditions, including radiotherapy and chemotherapy. In addition, the membrane system is essential for mitochondrial integrity to make the mitochondrial network more efficient in providing energy and required macromolecules. In this section, we systematically review the engagement of mitochondrial dynamics in cancer drug resistance.

**Mitochondrial biogenesis and turnover in drug resistance**

Mitochondrial biogenesis and turnover are two opposing processes that work in concert to regulate mitochondrial mass, function, and quality regulating the biogenesis of new mitochondria and the removal of
damaged mitochondria in a time-dependent manner. Mitochondrial biogenesis is regulated by the coordinated transcription of mitochondrial nuclear genes, in which PGC-1α plays a central regulatory role [86]. Reduced cellular bioenergetic output usually triggers mitochondrial biogenesis by activating AMPK to furnish OXPHOS and ATP production. In addition, oncogenes such as K-Ras and C-Myc are also involved in regulating mitochondrial biogenesis and increasing intracellular biosynthesis and respiration, thereby promoting tumorigenesis [87]. In particular, c-Myc controls the transcription of approximately 400 mitochondrial-related genes, thus regulating mitochondrial biogenesis [88]. These transcription networks provide metabolic flexibility for cancer cells to facilitate their adaptation to a hostile microenvironment and ultimately reduce the effectiveness of tumor treatment.

The most well-studied regulator involved in tumor drug resistance is PGC-1α, which facilitates tumor cell survival and metastasis under environmental stress by mediating mitochondrial biogenesis and OXPHOS [89, 90, 92]. Previous studies found that mutations in B-Raf or N-Ras in melanoma confer chemoresistance to MEK inhibitors by switching the metabolic mode to OXPHOS through upregulating PGC-1α or TFAM (transcription factor A, mitochondrial) to meet their bioenergy requirements [91, 93]. Similarly, upregulation of mitochondrial biogenesis and OXPHOS could augment tolerance to stimuli such as radiotherapy and ultraviolet radiation [94]. These studies demonstrate the critical role of adaptive mitochondrial biogenesis in drug-resistant capacity and highlight the potential of targeting mitochondrial OXPHOS for improving drug efficacy.

The maintenance of mitochondrial quality is also ensured by mitophagy, a programmed degradative process for eliminating excessive or defective mitochondria. Generally, the “eat me” signal on damaged mitochondria directly triggers mitophagy machinery by membrane depolarization and a cascade of phosphorylation and ubiquitination events to remove cytotoxic cellular components and maintain energy balance in the cell. It shares a common core mechanism with macro-autophagy but depends on specific mitophagy receptors, including the classical PTEN-induced putative kinase 1 (PINK1)-Parkin pathway [95, 96], and several other receptors, including Bcl-2/adenovirus E1B 19 kDa interacting protein 3 (BNIP3/NIX), FUN14 domain-containing protein 1 (FUNDCl), and Bcl-2-like protein 13 (BCL2L13). While these receptors have been well demonstrated to elicit mitophagy and facilitate tumor progression [97–99], they were proven to confer resistance of cancer cells to a variety of commonly used chemotherapy drugs, such as 5-fluorouracil (5-fu), cisplatin, and doxorubicin (Dox), by triggering mitophagy [64, 100, 101]. For example, the highly activated ATAD3A-PINK1/Parkin signaling pathway under hypoxic conditions confers tolerance of liver cancer cells to sorafenib [102]. In esophageal squamous cell carcinoma (ESCC) patients, PINK1-mediated mitophagy promotes tumor cell survival under neoadjuvant therapy [103]. Interestingly, PINK1 could recruit ARHI, rather than Parkin, to trigger mitophagy and ultimately lead to drug resistance in breast and lung cancer cells [104]. Several other emerging receptors, such as FUNDC1 and Galectin-1, have been reported to be upregulated to promote resistance to cisplatin and ionizing radiation by eliciting mitophagy [105]. In addition, the upregulation of these receptors relies on a series of stress-adaptive transcriptional programs mediated by p53, NF-κB, and STAT1/2 [106]. It would be of interest to further explore the regulatory role of these networks in regulating mitophagy and their potential role in drug resistance.

Mitochondrial fusion and fission in drug resistance

Mitochondrial fusion and fission allow mitochondria to constantly form networks or fragments according to cellular metabolic requirements. In general, fusion is commonly triggered by huge energy requirements, mediated by dynamin-related GTPases, optic atrophy 1 (OPA1) for IMM and mitofusin (MFN) 1 and 2 for OMM, resulting in a hyperfused mitochondrial network with increased mtDNA integrity, mitochondrial respiration, ATP production, and mitochondrial membrane potential (MMP) [107, 108]. Mitochondrial fission is mainly mediated by dynemein-related protein 1 (DRP1) and fission protein homologous protein 1 (FIS1) and has been shown to coordinate with mitophagy or apoptosis, facilitating the elimination of damaged mitochondria, the redistribution of mtDNA, and the mobility of mitochondria [109–113]. These two opposing processes are tightly organized in response to stressors, thus engaging in tumor progression in a context-dependent manner [114–116]. For instance, the increase in mitochondrial fission caused by hypoxia has been shown to enhance the invasion of breast cancer [117].

Recent advances in mitochondrial medicine highlight the engagement of mitochondrial fusion and fission in mediating metabolic adaptation to chemotherapeutic agents in tumor cells. The relevance of mitochondrial fusion in chemoresistance is primarily evidenced by the upregulation of OPA1 and MFN1/2 expression, as well as interconnected mitochondrial networks in drug-resistant cancer cells. For instance, upregulated OPA1 confers resistance to cytochrome c release upon prolonged venoclax treatment in acute myeloid leukemia (AML) cells [118]. Consistently, upregulated MFN2 and increased
OXPHOS have been found in cancer cells that survive chemotherapy [119, 120]. Several other factors have been reported to promote cancer drug resistance by triggering mitochondrial fusion. For example, circulating leptin protein activates induced myeloid leukemia cell differentiation protein (MCL1, a member of the anti-apoptotic protein BCL2 family) to induce mitochondrial fusion, thereby promoting tumor cells to survive during gemcitabine treatment [121].

Increasing evidence also shows the pivotal role of mitochondrial fission in chemoresistance [60, 122]. One of the best examples is that phosphorylation of DRP1 induces mitochondrial fragmentation to promote metabolic adaptation, thus protecting cancer cells from chemotherapy agents [123–125]. Phosphorylation or activation of several upstream kinases, such as AMPK, cyclin B1/Cdk1, ERK1, and DRP1, is involved in mitochondrial fission-mediated chemoresistance [61, 126]. Since mitochondrial fission and fission represent two opposing systems, their balance and role in cellular fate are carefully orchestrated by specific cellular metabolic requirements. Therefore, more insights into the regulatory patterns of mitochondrial fusion and fission and their effect in chemotherapy are necessary to develop therapies offering improved clinical outcomes for cancer patients.

Inter-organelle contact sites, mitochondrial trafficking, and transfer in drug resistance
Mitochondria dynamically form contacts with various intracellular organelles to maintain cell homeostasis by fine-tuning Ca\(^{2+}\) transfer, phospholipid biosynthesis, ROS signaling, mitochondrial quality control, and mtDNA synthesis [127–133]. Such cellular membrane interactions are extensive and play the essential role in cell adaptation to metabolic stress [134].

The mitochondrial-associated endoplasmic reticulum (ER) membrane (MAM) is the most well-studied membranous system coordinating with a series of proteins and factors to maintain proper mitochondrial Ca\(^{2+}\) uptake which correlates with resistance to chemotherapy [135]. Mitochondrial Ca\(^{2+}\) uniporter complex (MCUC) subunits (MCU, MICU1, MICU2, EMRE, and MCUb) cooperate to maintain mitochondrial Ca\(^{2+}\) homeostasis, and their relevance to drug resistance is condition dependent [136–139]. For example, downregulation of MCU was demonstrated to confer resistance by restricting the transport of Ca\(^{2+}\) to the mitochondria in HeLa cells [140]. However, the interaction of MCU with receptor-interacting protein kinase 1 (RIPK1) can increase mitochondrial Ca\(^{2+}\) uptake, resulting in increased proliferation of colorectal cancer cells [141]. Additionally, MCUR1-mediated mitochondrial Ca\(^{2+}\) signaling was reported to facilitate cell survival of hepatocellular carcinoma (HCC) upon pro-apoptotic stimuli [137]. Several other recognized mitochondrial proteins, such as MFN2 and voltage-dependent anion-selective channel proteins (VDACs), were identified as important MAM proteins that might be involved in tethering MAMs and facilitating mitochondrial fission, mitophagy, and mitochondrial positioning [142, 143]. Moreover, there is mitochondrial contact with other organelles, such as peroxisomes, and lipid droplets, in response to metabolic stress. For example, “lipid droplet mitochondria” can help mitochondria provide energy by burning fatty acids (FAs) to support the TCA cycle [144]. Therefore, we conclude that exploring mitochondria-associated tethering systems could expand the understanding of mitochondrial dynamics and provide new targets for tumor intervention.

The proper localization of organelles is often crucial to their activity and function [145]. Numerous studies have shown that the movement and subcellular location of mitochondria can affect tumor cell polarity, morphology, and mobility capacity [146–150]. Mitochondrial stress responses drive strategic mitochondrial redistribution to fulfill bioenergetic needs, Ca\(^{2+}\) homeostasis, ROS buffering, and signal transduction, thus promoting the adaptation of tumor cells to the harsh tumor microenvironment [150–156]. A typical example is that of mitochondria migrating to the invasive front of metastatic tumor cells [157]. For example, the NF-kB-inducing kinase (NIK)-DRP1 axis could mediate the fission and subsequent directionally positioning of mitochondria to the cell periphery to promote the migration of a variety of tumors [151, 158]. In addition, the trafficking of mitochondria along the cytoskeleton could protect cells from detrimental ROS production [155, 159]. Notably, mitochondrial trafficking occurs to endow tumor cells for survival and metastasis upon drug abuse [160]. For instance, activated Akt promotes mitochondria positioning along the cytoskeleton to provide an effective “regional” energy source, thus fueling resistance and even adaptive cell invasion in response to PI3K inhibitors [148]. Intensive studies on this “spatiotemporal” model of mitochondria may deepen our understanding of the subcellular accumulation of mitochondria as an adaptive process and may provide a viable strategy to increase anticancer efficacy in the clinic.

Recent studies have shown that mitochondrial dynamics are accompanied by intercellular mitochondrial transfer [161–163]. This transfer process is achieved through several mechanisms, including gap junctions, extracellular vesicles (EVs), and tunneling nanotubes (TNTs) [164–169]. TNTs, the transient cytoplasmic extensions, are the major cellular structure that mediate intercellular mitochondrial transfer [170]. The mitochondrial transfer process usually increases the OXPHOS output and ATP
level of recipient cells. As a consequence, recipient cancer cells exhibit a survival advantage and resistance to stress [171–173]. Moschoi et al. observed that AML cells acquire intact mitochondria from marrow stromal cells (MSCs) to maintain their own mitochondrial function and survive during cytarabine treatment [174]. Several other tumors can also despoil mitochondria from MSCs and obtain resistance to chemotherapeutics [172]. In addition, it has been proposed that mitochondria transfer from bone marrow stromal cells (BMSCs) to multiple myeloma (MM) cells, which can also contribute to chemoresistance [175, 176]. Consistently, in breast cancer, mitochondrial transfer promotes resistance to doxorubicin [177], and mtDNA in exosomes derived from hormonal therapy-resistant breast cancer cells leads to endocrine therapy resistance. Intercellular transfer of mitochondria expands the influence of mitochondria on tumor metabolism, suggesting that targeting mitochondrial transfer could represent a more reasonable and effective antitumor strategy.

Mitochondrial retrograde signaling in drug resistance
Mitochondrial dynamic changes are positively regulated by nuclear coding factors, while recent advances underline that retrograde signaling activated by mitochondrial dysfunction can modify nuclear gene expression and subsequent cell behavior [59, 178]. In fact, it serves as an adaptive mechanism for tumor cells to sense and mitigate mitochondrial stress, thus participating in tumor survival, metastasis, and drug resistance.

Retrograde reactions
The signals from mitochondrial dysfunction, especially mutation/deletion in mtDNA, are usually relayed to the nucleus by TCA cycle intermediates, ATP, Ca^{2+} or ROS, which activate specific kinases to initiate transcriptional regulation of nuclear genes or posttranslational modification of key proteins (e.g., histone acetylation) [179–181]. The most well-studied example is the activation of AMPK triggered by a decrease in ATP levels, which elicits PGC-1α-mediated transcription of genes responsible for energy metabolism, mitochondrial synthesis, and the quality control system [182, 183].

As mentioned above, mitochondria are essential for maintaining intracellular Ca^{2+} levels. Disruption of MMP caused by deletion of the electron transport chain complex or drug insult led to leakage of Ca^{2+} into the cytoplasm. Intracellular free Ca^{2+}, on the one hand, activates multiple oncogenic signaling pathways, including RAC-alpha serine/threonine-protein kinase (AKT) and phosphatidylinositol 3-kinase (PI3K), to upregulate the expression of glucose transporters, such as GLUT1 and GLUT4, thereby promoting the metabolic switch to glycolysis and the survival of cancer cells [184–186]. On the other hand, Ca^{2+} signaling activates NF-κB and T cell nuclear factor (NFATC) signaling to facilitate the transcription of Ca^{2+} transport and storage-related proteins [187, 188].

ROS can directly manipulate cellular redox homeostasis and act as second messengers to regulate cellular physiological and pathological processes [189–191]. For example, ROS elicited by mtDNA depletion could activate the NRF2 signaling pathway and the multidrug resistance proteins MRPs 1 and 2 to help tumor cells fight against ROS and survive under cisplatin, doxorubicin, and SN-38 treatment [192]. In addition, ROS modulate the expression of PGC-1α to promote OXPHOS, thus conferring cisplatin resistance in ovarian cancer cells [193]. Together, these studies have linked mtDNA mutations/deletion with changes in sensitivity of cancer cells to chemotherapy, thus providing a new perspective on modulating drug resistance.

Mitochondrial nuclear feedback and mitochondrial stress-relieving response
Mitochondria have evolved protein quality control systems to maintain mitochondrial integrity by ensuring proper folding, assembly, and circulation of mitochondrial proteins in response to exogenous or endogenous stressors. This process tightly relies on feedback regulatory loops, including the mitochondrial unfolded protein stress response (UPRmt) [194], proteolytic stress responses [195], and the heat shock response of mitochondrial chaperones [196]. These mechanisms are deregulated due to altered signaling to confer cancer cell survival, which ultimately contribute to tumor progression and drug resistance. This could be due to several proposed mechanisms, including continuous activation of NF-κB and molecular chaperone systems and mutations in the catalytic sites that contribute to resistance to proteasome inhibitors. For instance, a recent study has suggested that the mitochondrial oxidoreductase ferredoxin 1 (FDX1) maintains mitochondrial metabolism to promote the adaptation of tumor cells to the proteasome inhibitor elesclomol [197]. More investigations revealing the mechanisms employed in the quality control system of mitochondrial protein might offer unique strategies for improving therapeutic efficacy in cancer treatment.

Mitochondrial-derived peptides
Recently, mitochondria-derived peptides (MDPs, short open reading frames (sORFs) of mitochondrial genome) have been identified and implicated in stress response, metabolic regulation, and other biological processes. In response to cellular stress, these peptides can even directly manipulate nuclear gene expression [198], which
expands the paradigm of mitochondrial nuclear communication. Several MDPs have been identified, including Humanin [199], humanin-like peptides (SHLP) 1–6 [200], and MOTS-c [201–203]. Among them, humanin was reported to protect cells from oxidative stress and mitochondrial dysfunction [204]. SHLP2 and SHLP3 exert similar cytoprotective effects by maintaining mitochondrial function and combating excessive ROS levels [202, 205]. In particular, MOTS-c was reported to translocate to the nucleus under metabolic stress such as glucose deprivation and oxidative stress [206]. In the nucleus, MOTS-c regulates the transcription of a broad range of genes, including those with antioxidant response elements (AREs) and other anti-inflammatory-associated genes, to initiate the stress adaptation program. A considerable number of studies have now proven that MDPs are intrinsically linked to tumor progression, and targeting MDPs holds potential to improve the efficacy of chemotherapeutics [207, 208].

Mitochondria-mediated CSC properties in drug resistance

It is well established that CSCs contribute substantially to the refractory features of cancer. Under pharmacological treatment, mitochondria function as a central hub to maintain the survival and self-renewal capacity of CSCs, resulting in drug resistance and tumor recurrence [209]. For example, it has been reported that oncogenic Myc cooperated with MCL1 to maintain chemoresistance of CSCs in triple-negative breast cancer (TNBC). Further studies found that Myc and MCL1 upregulated the levels of mitochondrial OXPHOS and promoted ROS generation, which contributed to the accumulation of HIF-1α and the subsequent maintenance of CSC properties [210]. Moreover, PGC-1α, a critical regulator of mitochondrial biogenesis, has been demonstrated to enhance stem cell-like characteristics and chemoresistance to cisplatin in ovarian cancer [211]. In addition, increased levels of mitochondrial mass were found in a subtype of chemo-resistant breast cancer cells enriching in several known CSC markers, implying the potential of targeting mito-high CSC population for cancer therapy [212]. Therefore, investigation of mitochondrial function in regulating CSCs holds the promise to benefit the development of novel CSC-targeted strategies for reversing cancer drug resistance.

In summary, a large body of evidence has indicated the important role of mitochondrial dynamics in the adaptive mechanism of cancer cells in response to a challenging environment, which is expected to expand the understanding of cancer drug resistance phenomena [91, 213–216]. Further investigations deciphering specific mitochondrial-related mechanisms implicated in the resistance could hopefully benefit the identification of possible biomarkers for the early prediction of cancer drug resistance and hold promise to target mitochondria for overcoming cancer drug resistance.

Targeting mitochondria to overcome cancer drug resistance: the current status and challenges

The mitochondrial ETC fuels cellular energy demands by utilizing intermediates from various metabolic pathways, including the TCA cycle and FAO, and couples the generation of macromolecules such as amino acids and nucleotides [217–219]. Thus, dynamic regulation of mitochondria involves robust metabolic and redox alterations, as well as changes in ion (e.g., Fe^{2+}, Ca^{2+}) homeostasis. Increasing knowledge that these critical processes are linked to tumor transformation makes mitochondria an attractive therapeutic target. In this section, we will summarize current mitochondrial therapeutic targets and their proposed inhibitors (Fig. 3, Table 1), with a particular emphasis on the role of small-molecule inhibitors in targeting mitochondria to overcome cancer chemoresistance.

Targeting mitochondrial ETC

The mitochondrial ETC complexes I–V (hereafter CI-V) bypass electrons to generate energy and are the major source of mitochondrial ROS [250, 251]. Disruption of the ETC inevitably triggers apoptosis and perturbs the cellular redox balance and therefore provides a possible strategy for eliminating cancer cells [252].

Complex I

Mitochondrial complex I (CI), the largest complex of the ETC, transfers TCA cycle-derived electrons from NADH from the UbQ and maintains the proton gradient on the MIM. Several inhibitors including piericidin, tamoxifen, metformin, and ME-344 that directly target the respiratory complex I have gained momentum as potential antitumor therapeutics. Metformin, an antidiabetic drug has now been repurposed as an anticancer drug and was observed to inhibit CI. Many preclinical and clinical studies have demonstrated its excellent antitumor efficacy in managing resistance caused by chemotherapeutics, including cisplatin, Dox, and 5-FU (NCT00897884, NCT02437656; Table 2) [253–256]. In addition, a recent phase II clinical trial observed that combinational use of metformin with standard epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy significantly improved both progression-free survival and overall survival in patients with advanced lung adenocarcinoma (NCT03071705; Table 2) [257]. Consistently, metformin-sensitized lymphoma to isocitrate dehydrogenase (IDH) mutant inhibitors and increased the sensitivity of lymphoma to AZD3965, a monocarboxylate
transporter (MCT1) inhibitor, by disturbing mitochondrial complex I and bioenergetics, thus providing a scientific rationale for combinatory mitochondrial-targeted therapies to overcome drug resistance in human lymphoma [53, 258].

Complex II

Complex II (CII, succinate dehydrogenase), the smallest respiratory complexes, is a membrane-bound component of the TCA cycle that permits the oxidation of succinate to fumarate. Compounds that induce substantial ROS generation from CII are the emerging anticancer drugs. For example, alpha-tocopheryl succinate (α-TOS), a compound targeting UbQ-binding sites in CII, has been demonstrated to disturb CII for eliciting mitochondrial permeabilization and apoptosis, thus showing significant potential in overcoming drug resistance in various tumors [226, 259, 260]. In particular, based on the knowledge that α-TOS targets UbQ-binding sites, a more specific mitochondrial-targeted analogue, MitoVES, was designed for efficiently suppressing tumors by disturbing mitochondria [261, 262].

Complex III

CIII, similar to CI, functions by pumping protons across the MIM and contributing to the proton gradient. It has been also identified as target for anticancer drugs. Antimycin A is the most classic CIII inhibitor to trigger apoptosis for effectively eliminating cancer cells [263, 264]. Resveratrol, a plant-derived polyphenol, exhibited considerable antitumor efficacy by efficiently inhibiting ETC complexes, especially CIII to induce apoptosis and disturb multiple cellular processes in primary and resistant cancer cells [265–267]. Importantly, the anticancer potential of resveratrol is being investigated in clinical trials for the treatment of colorectal, liver, and breast cancer (NCT0025633, NCT00433576, and NCT03482401; Table 2).
Complex IV

CIV ensures the final step of electron transport in ETC to maintain the proton gradient and mitochondrial membrane potential. Several compounds have been observed to modulate the mRNA or protein expression of CIV subunits and thereby induce apoptosis in tumor cells. Fenretinide (also named as N-(4-hydroxyphenyl) retinamide, 4-HPR) and its analogue are perhaps the most well-documented category to downregulate CIV by destabilizing the mRNA transcript [268], thereby inducing ROS-mediated apoptosis to combat tumors in both preclinical and clinical studies (NCT00004154, NCT00009971, and NCT00077402; Table 2) [269, 270]. In particular, Fenretinide has been reported to eliminate ABT-737-resistant cell lines via ROS generation and MCL1 reduction and thus has synergetic effect with ABT-737 to enhance mitochondrial apoptotic cascade in acute lymphoblastic leukemia (ALL) [271].

Complex V

CV, the ATP synthase, directly catalyzes ATP production using the proton gradient maintained by complexes I–IV, thus supplying the cell with essential energy. Besides oligomycin and its derivatives, several newly identified CV inhibitors, including 3,30-diindolylmethane (DIM), Bz-423, were proposed to fight tumors and even those with drug resistance [230, 272]. Notably, there are compounds that could inhibit different complexes of ECT. For example, resveratrol is also reported to bind to CV and induce Bcl-2-mediated apoptosis [273]. In addition, Gboxin, an OXPHOS inhibitor, is observed to interact with several respiratory chain proteins spanning CI, CII, CIV, and CV, thereby suppressing tumor growth [274]. Although it remains to be known whether these ETC inhibitors will be effective in humans, emerging studies provide excellent prospects for their application in cancer therapy and drug resistance eradication.

Mitochondrial redox balance

ROS are intrinsically involved in tumor progression by modulating cell survival, secondary signaling networks, and genetic instability/mutations [275]. Mitochondria function as a major contributor to endogenous ROS due to the large electron flow in the ETC and constant metabolism alterations involved in numerous enzyme-catalyzed reactions. Mitochondrial redox balance is typically mediated by cellular antioxidants, such as glutathione (GSH), glutathione peroxidases (GPx1 and GPx4), and glutathione reductase [276–282]. Emerging observations suggest that heightened levels of ROS contribute to drug resistance. For instance, gefitinib resistance was demonstrated to be associated with mitochondrial dysfunction.

| Table 1  | Summary of mitochondrial targets for cancer therapy |
|----------|-----------------------------------------|
| Category (Mitochondria signaling pathway) | Targets | Inhibitors and Refs |
| Mitochondrial ETC and OXPHOS | Complex I | Piericidin [220]; rotenone [221]; deguelin [222]; tamoxifen [123, 223]; metformin [224]; ME-344 [225] |
| | Complex II | α-TOS [226]; MitoVES [227] |
| | Complex III | Resveratrol [228]; |
| | Complex IV | Fenretinide [229]; |
| | Complex V | BZ-423 [230] |
| Targeting the mitochondrial metabolic pathway | Heme synthesis | Cycloamine tartrate (CycT) [231]; HasA [232] |
| | 1C metabolism (SHMT1 and SHMT2) | AGF291, AGF320, and AGF347 [233, 234]; lometrexol [235] |
| | DHODH | lelfunomide [236, 237] |
| | Nucleotide biosynthesis | IACS-010759 [238] |
| | TCA cycle (α-ketoglutarate dehydrogenase (α-KGDH) and pyruvate dehydrogenase (PDH)) | CPI-613 [239] |
| | Glutaminase (GLS) | CB-839 [240], bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTE5) [241] |
| | Glutamate-pyruvate transaminase 2 (GPT2) | Aminoxyacetate (AOA) [54] |
| Redox balance | NADH-ubiquinone oxidoreductase | SMIP004-7 [242]; |
| | VDACs and ANT | lonidamine[243], steroid analogs [244] |
| | Na+/Ca2+ exchanger | CGP-37157 [245] |
| | Bcl-2 | Gossypol [246] |
| | S100A4 | Niclosamide [247] |
| Mitochondrial membrane proteins | Hexokinase II | 3-bromopyruvate [248]; 2-Deoxyglucose (2-DG) [249] |
| Inhibitor | Target | Cancer type | ClinicalTrials.gov Identifier | Status            |
|----------|--------|-------------|-------------------------------|-------------------|
| Metformin | CI     | Breast cancer | NCT04559308 | Recruiting        |
|          |        | Breast cancer | NCT00897884 | Completed         |
|          |        | Rectal cancer | NCT02437656 | Completed         |
|          |        | etc.          |                 |                   |
| VLX600   | ETC    | Refractory cancer | NCT02222363 | Terminated        |
| Fenretinide | CIV  | Advanced or metastatic hormone refractory prostate cancer | NCT00077402 | Completed         |
|          |        | Lung cancer | NCT00009971 | Completed         |
|          |        | Bladder cancer | NCT00004154 | Completed         |
|          |        | etc.          |                 |                   |
| Resveratrol | CII   | Colon cancer | NCT00256334 | Completed         |
|          |        | Liver cancer | NCT00433576 | Completed         |
|          |        | Breast cancer | NCT03482401 | Completed         |
| Tigecycline |       | Acute myeloid leukemia | NCT01332786 | Completed         |
| Gamitrinib |       | Lymphoma, advanced solid tumor | NCT04827810 | Recruiting        |
| CPI-613  | TCA cycle, PDH | Biliary tract cancer | NCT04203160 | Recruiting        |
|          |        | Advanced hematologic malignancies | NCT01034475 | Completed         |
|          |        | Recurrent small cell lung cancer | NCT01931787 | Completed         |
|          |        | etc.          |                 |                   |
| Dichloroacetate | PDK | Head and neck cancer | NCT01163487 | Completed         |
|          |        | Squamous cell carcinoma of the head and neck etc. | NCT01386632 | Completed         |
| IACS-010759 | CI, TCA cycle | Advanced malignant solid neoplasm; Anatomic stage IIIA breast cancer | NCT03291938 | Completed         |
|          |        | Recurrent acute myeloid leukemia etc. | NCT02882321 | Active, not recruiting |
| Leflunomide | DHODH | Breast neoplasms | NCT03709446 | Recruiting        |
|          |        | Prostate cancer | NCT00004071 | Completed         |
|          |        | Brain and central nervous system tumors etc. | NCT00003775 | Completed         |
| ONC201   | OXPHOS | Endometrial cancer recurrent | NCT03485729 | Recruiting        |
|          |        | Triple-negative breast cancer; endometrial cancer; hormone receptor positive, HER2 negative breast cancer | NCT03394027 | Completed         |
|          |        | Recurrent neuroendocrine tumor; metastatic neuroendocrine tumor etc. | NCT03034200 | Active, not recruiting |
| Tamoxifen | ETC   | Breast cancer | NCT00286117 | Completed         |
|          |        | Estrogen receptor positive breast cancer | NCT02989868 | Completed         |
|          |        | Bladder cancer | NCT02197897 | Completed         |
| ME-344   | ETC    | Breast cancer; human epidermal growth factor 2 negative carcinoma of breast; early-stage breast carcinoma etc. | NCT02806817 | Completed         |
| Gossypol | Bcl-2 family proteins | Extensive stage small cell lung cancer; Recurrent small cell lung cancer etc. | NCT00033722 | Completed         |
| Lometrexol | SHMT2  | Lung cancer; Unspecified adult solid tumor, protocol specific | NCT00024310 | Unknown           |
in lung cancer cells [283]. Conventional chemotherapies, such as 5-FU and cisplatin, are designed to kill cancer cells via ROS-dependent mechanisms. In that context, enhanced ROS levels could maximize antitumor efficacy. For example, SMIP004-7 targets NADH:ubiquinone oxidoreductase to improve the immunotherapeutic effect of PD-1 in triple-negative breast cancer [242]. Destroying the redox balance is perhaps the essence for modulating mitochondrial ROS to benefit cancer therapy. In view of this, redox status during treatment and the basal mitochondrial ROS range may provide important clues for guiding rational intervention strategies. Selective targeting of ROS-specific organelles, as well as dynamic ROS delivery, might be beneficial for preventing drug resistance and effectively eliminating cancer cells.

**Targeting the mitochondrial metabolic pathway**

**Nucleotide biosynthesis**

Targeting mitochondrial ETC-linked metabolic pathways, such as nucleotide metabolism, also contributes to improved antitumor efficacy. One-carbon (1C) metabolism coordinates with serine synthesis to provide glycine and tetrahydrofolate methyl donors, namely methylene-THF (5,10-CH₂-THF) and formyl-THF (10-CHO-THF), for nucleotide synthesis. As essential enzymes in 1C metabolism, cytosolic SHMT1 and mitochondrial SHMT2 have attracted much attention. Several inhibitors, including AGF291, AGF320, and AGF347, have been developed to target these enzymes, and their antitumor efficacy has been established for lung, colon, and pancreatic cancer cells [233, 234, 284]. Intriguingly, folate inhibitors such as lometrexol have also been found to reduce SHMT1 and SHMT2 activity [235]. Several clinical trials are undergoing to investigate the use of lometrexol in advanced solid tumor (NCT00024310; Table 2).

In addition, efforts have been made to inhibit nucleotide metabolic enzymes, such as the intramitochondrial key pyrimidine synthesis-related enzyme, dihydroorotate dehydrogenase (DHODH). Leflunomide exhibited antitumor activity in prostate cancer mouse model by inhibiting DHODH [236]. Additionally, a phase I clinical study showed leflunomide had considerable activity toward myeloma with manageable side effects (NCT02509052; Table 2). Furthermore, IACS-010759, a mitochondrial CI inhibitor, was developed to induce apoptosis in brain cancer and AML, likely caused by energy depletion and reduced aspartate production that led to impaired nucleotide biosynthesis [238]. Combinational use of IACS-010759 with lactate dehydrogenase (LDH) inhibitor could overcome oxidative rewiring and show a synergistic therapeutic effect [49]. Key enzymes involving in nucleotide metabolism could also play a “part-time role” in other mitochondrial processes (e.g., SHMT2 participating in mitochondrial translation) [285–287]. The antitumor effects of nucleotide metabolism inhibitors could be manifold. As such, further efforts are urgently needed to screen for candidates targeting nucleotide metabolism for cancer management.

**TCA cycle**

The mitochondrial TCA cycle integrates multiple fuel sources to synthesize nucleotide, amino acid, lipid, and heme. Several TCA cycle inhibitors have been under investigation and predicted to be efficacious. Among them, CPI-613, a lipoate analog that targets two enzyme complexes of the TCA cycle (α-ketoglutarate dehydrogenase (α-KGDH) and pyruvate dehydrogenase (PDH)) [288], exerts anticancer activity in pancreatic cancer and AML [289]. Notably, CPI-613 could sensitize AML cells to cytarabine and mitoxantrone, representing a promising approach for relapsed or refractory AML [239]. To date, clinical trials of CPI-613 for the treatment of advanced or recurrent tumor are ongoing, or have already been completed with satisfactory results (NCT04203160, NCT01034475, and NCT01931787; Table 2). Interestingly, a recent study reported that vitamin C modulates the activity of PDH and regulates the TCA cycle via interfering with PDK1-mediated phosphorylation of PDH in KRAS mutant colon cancer, suggesting a potential application for clinical management of chemoresistance to anti-EGFR therapy [290].

**Glutaminolysis**

Glutamine (Gln) can be converted to glutamate by glutaminase (GLS) and further metabolized to α-KG via glutamate dehydrogenase 1 (GLUD1), glutamate oxaloacetate transaminase 2 (GOT2) or glutamate-pyruvate transaminase 2 (GPT2), thus providing a major carbon source to replenish the TCA cycle [291–295]. Many classes of compounds that target mitochondrial Gln metabolism are being investigated for cancer treatment. GLS inhibitors have shown promising anticancer effect in preclinical models of cancer. For example, bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl) ethyl sulfide (BPTES), a GLS inhibitor, has been demonstrated to slow the growth of various types of tumors [296, 297]. Importantly, BPTES was observed to efficiently sensitize pancreatic cancer to 5-(tetradeoxylo)-2-furoic acid (TOFA, an acetyl-CoA carboxylase inhibitor) and β-Lap (an NADPH:quinone oxidoreductase (NQO1) inhibitor) via enhancing cancer cell apoptosis [241, 298, 299]. In particular, CB-839 (telaglenastat), another GLS inhibitor, has moved on to clinical trials and exhibits promise as potential drug for renal cell carcinoma (NCT03428217; Table 2), hematological malignancies (NCT03428217 et al. Journal of Hematology & Oncology (2022) 15:97
and NCT02071888; Table 2), non-small cell lung cancer (NSCLC) (NCT02071862; Table 2), and even those drug-resistant tumors (NCT03994902 and NCT03798678; Table 2). Recently, GPT2 has been demonstrated to promote cell survival by supporting the TCA cycle after GLS inhibition [54]. In that context, inhibition of GPT2 using aminooxycetate (AOA), a transaminase inhibitor, could thus sensitize cancer cells to BPTES.

Targeting Ca\(^{2+}\) homeostasis
Mitochondria have evolved Ca\(^{2+}\) influx and efflux systems to maintain cellular Ca\(^{2+}\) homeostasis. Proper mitochondrial Ca\(^{2+}\) ensures respiration efficacy and ATP production, while Ca\(^{2+}\) overload can induce mitochondria-mediated apoptosis [300–303]. Therefore, mitochondrial Ca\(^{2+}\) signaling pathways engage multifaceted roles in regulating cell fate and are beneficial for tumorigenesis. Studies are under way to identify the proteins involved in mitochondrial Ca\(^{2+}\) signaling pathways as alternative targets for cancer therapy, and to evaluate the potential for increasing the sensitivity toward chemotherapeutic treatment. Compounds that modulate mitochondrial porins such as VDACs and ANT, including lonidamine, arsenites, and steroid analogs, have been documented to disturb the mitochondrial Ca\(^{2+}\) balance and elicit mitochondrial apoptosis, thus showing potent antitumor efficacy as well as drug resistance overcoming activity [243, 244, 304]. In addition, a mitochondrial Na\(^{+}/Ca\(^{2+}\) exchanger inhibitor, CGP-37157, resulted in a persistent mitochondrial Ca\(^{2+}\) rise and may serve as a promising agent to overcome TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) resistance [245, 303]. In ovarian cancer cells, the overexpression of Bcl-2 attenuated cisplatin cytotoxicity by downregulating ER-mitochondrial Ca\(^{2+}\) signal transduction. Thus, targeting Bcl-2-mediated Ca\(^{2+}\) signal might be a potential approach to overcome drug resistance in ovarian cancer [305].

Current challenges in targeting mitochondria
The mitochondrion is perhaps the most challenging target for cancer therapy [306, 307]. The constant alterations in mitochondrial structure and position contribute greatly to the failure of targeted agents, the bias in drug toxicity, and drug dosage prediction [308]. For example, the doses of metformin that could reduce the proliferation of cancer cells in laboratory models (in vitro cell lines and in vivo mouse models) were 10- to 1,000-fold higher than those that are deemed safe clinically [309]. This makes it urgent to assess the efficacy and safety of higher doses of metformin to determine its clinical potential. Second, many mitochondrial inhibitors are delivered into the mitochondria depending on the MMP.

As such, imported drugs could inhibit ETC complexes and diminish the MMP, leading to decreased total agent importation [310, 311]. In addition, targeting the ETC is likely to be fraught with severe side effects. Some ETC inhibitors are considered neurotoxic, such as rotenone [312, 313], and some, such as cyanide, are even lethally toxic [314, 315]. In particular, IACS-010759, a CI inhibitor being advanced to clinical trials (NCT03291938 and NCT02882321; Table 2) [238, 316], has been associated with neuropathy and visual changes [49]. Moreover, metabolic plasticity promotes cancer cells to shift their metabolic features upon targeting specific metabolic vulnerabilities [317]. Furthermore, the selection of metabolic targets for therapeutic intervention has often been done in cell culture systems, where the metabolism of initial tumor-derived cells may be significantly affected by culture conditions [318]. These systems also do not recapitulate tumor heterogeneity and complex tumor–tumor–host interactions [47].

Strategies for overcoming mitochondria-targeting bottlenecks to combat drug resistance
As mentioned above, limitations in drug sources and drug targeting challenge the application of targeting mitochondria for improving therapeutic efficiency in cancer treatment. Therefore, researchers are seeking new strategies to achieve a competitive advantage in targeting mitochondria for cancer therapy. Redevelopment and reuse of old drugs (repurposing/repositioning) represent such an opportunity to replenish the inventory of mitochondrial-targeted antitumor drugs [224]. Besides, the use of targeted nanomedicines offers innovative therapeutic strategies to overcome multiple barriers and selectively transport drug molecules to the mitochondria [319, 320]. Additionally, mitochondrial transplantation is an emerging approach that exerts antitumor potential by restoring mitochondrial function [321].

Drug repurposing for overcoming mitochondria-targeting bottlenecks
Drug repositioning is a strategy to identify medications that were initially used for the treatment of other noncancer illnesses for tumor therapy, based on an accumulated understanding of their mechanisms of action [322–324]. The advantages of this approach include, but are not limited to, the already established pharmacokinetic, pharmacodynamic, and toxicity profiles, their rapid progress into clinical trials, the significantly lower associated development cost as well as a relatively less risky business plan [325–327]. In recent years, technological innovation combined with the development of big data repositories and the analytical methods, as well as the emergence of a variety of innovative computational methods and in
silico approaches, have greatly promoted the process of drug repurposing [328–331]. In this section, we present various promising repurposed non-oncology drugs that disrupt specific mitochondrial components and their functions for preclinical or clinical management of cancer drug resistance (Table 3).

**Repositioning anti-diabetic drugs**

Metformin, an approved anti-diabetic drug which has been used in cancer therapy, is one of the most successful repurposed drugs [332–335]. Several signaling pathways, including insulin/IGF1, NF-kB, AMPK/mTOR/PI3K, Ras/Raf/Erk, Wnt, Notch, and TGF-β signaling, have been identified to be involved in its antitumor effect [336–344]. Besides, metformin has been well demonstrated to target mitochondria and induce cytotoxic effects [345–348]. Numerous preclinical studies and clinical trials are investigating the therapeutic potential of metformin in many types of tumors [349–351]. Consistent with this, metformin was proven to enhance the anticancer effect of radio- or chemotherapy. For instance, Lee et al. observed that metformin could overcome resistance to cisplatin by downregulating RAD51 expression, representing a novel strategy in TNBC management [255]. In addition, in NSCLC, metformin acts synergistically with sorafenib to inhibit cell proliferation by activating AMPK, which holds significant potential to be tested in prospective clinical trials [352].

Other biguanides also exhibit enhanced antiproliferative or radio-sensitizing effects in cancer cells. For instance, HL156A, a metformin analog, markedly decreased MMP and induced ROS levels to activate caspase-3- and caspase-9-mediated apoptosis, thus suppressing tumor growth [353]. This study suggests the potential value of HL156A as a candidate for the treatment of oral cancer. Phenformin, a potent mitochondrial ETC inhibitor, also displayed remarkable anticancer activity against several tumors [354]. In colorectal cancer, phenformin could overcome hypoxic radio resistance through inhibition of mitochondrial respiration [355]. In breast cancer, phenformin synergistically decreased respiration and ATP production with oxamate, an inhibitor of lactate dehydrogenase, to inhibit tumor growth [356]. Furthermore, phenformin and oxamate displayed synergistic anticancer effects through simultaneously inhibiting mitochondrial complex I and cytosol LDH in this study.

Moreover, several other anti-diabetic drugs have also been successively repurposed for cancer therapy and drug resistance management. Exendin-4 (Exe-4), a GLP-1 receptor agonist, was reported to elevate mitochondrial ROS and trigger subsequent apoptosis, which attenuated hyperglycemia-induced chemoresistance and sensitized human endometrial cancer cells to cisplatin treatment [357]. Canagliflozin, another anti-diabetic drug, was identified to inhibit the proliferation of lung and prostate cancer cells, alone or in combination with ionizing radiation or chemotherapy using docetaxel by inhibiting mitochondrial C1 supported respiration [358]. In addition, piperazine also targeted mitochondria to inhibit oxygen consumption, thus exhibiting an additive effect on inhibiting cell proliferation in combination with the glycolysis inhibitor 2-deoxyglucose (2-DG) [359].

Overall, repurposing anti-diabetic drugs provides a plethora of candidates to suppress the growth of many types of tumors by targeting mitochondria. These drugs could not only increase the efficacy of standard therapies, but also reduce their side effects by potentially modulating metabolic plasticity.

**Repositioning antimicrobial agents**

Antimicrobial therapeutics, including antibiotics, antihelmintic and antifungal drugs, have been repurposed against tumors (e.g., breast, liver, colorectal and lung cancers, glioblastoma, multiple myeloma, and leukemia). A particularly important mechanism underlying their anticancer effects is interfering with mitochondrial function [360]. Examples of antibiotics that suppress cancer by altering mitochondria include the chloramphenicol family and tetracycline [361]. For instance, tigecycline preferentially inhibits the translation of mtDNA-encoded proteins to restrain the mitochondrial respiratory chain, causing mitochondrial dysfunction and increased oxidative stress, thus providing a therapeutic strategy for overcoming chemoresistance in human renal cell carcinoma and ovarian cancer [362, 363]. The antibiotic drug levofloxacin has also been repurposed to inhibit proliferation and trigger apoptosis of lung cancer cells by inducing mitochondrial dysfunction and oxidative damage [364].

In addition, several antihelmintic compounds were observed to interfere with mitochondria and combat with tumors. For instance, niclosamide could induce mitochondrial dysfunction and activate Bax and caspase-3, which attenuates migratory and invasive behaviors and promote apoptosis in thyroid cancer and chondrosarcoma tumors [365, 366]. Another antihelmintic drug, ivermectin, was suggested to inhibit angiogenesis, growth, and survival by decreasing mitochondrial respiration, membrane potential, and ATP levels [367]. The well-documented antimalarial agent artesiminin and its derivatives also possess potent anticancer activity through mitochondria-related pathways, manifesting as significantly reduced MMP, increased intracellular ROS and Ca”“ levels, and upregulated apoptosis-associated proteins [368, 369]. In particular, artesunate was reported to induce PINK1-dependent mitophagy to alter...
**Table 3**  List of repurposed mitochondria-targeted drugs

| Original application | Repurposed drug | Effects on mitochondria | Effects on cancer | Cancer type |
|----------------------|-----------------|--------------------------|------------------|------------|
| Antidiabetes         | Metformin       | ↓Complex I activity, ↓Respiration, ↓ATP production | ↓Cell growth, ↑cell death, overcome chemoresistance | Breast cancer, colorectal cancer, lung cancer, ovarian cancer, etc. |
|                      | HL156A          | ↓MMP, ↑ROS, ↑caspase-3 and caspase-9 | ↑Apoptosis, antiproliferative, Radio sensitizing | Oral cancer |
|                      | Phenformin      | ↓Complex I, ↓respiration, ↓ATP production | Antiproliferative, radio sensitizing, overcome chemoresistance | Colorectal cancer, breast cancer |
|                      | Exendin-4 (Exe-4) | Mitochondrial dysfunction, ↑ROS, | Overcome chemoresistance | Endometrial cancer |
|                      | Canagliflozin   | ↓Complex I, ↓respiration | Antiproliferative, Radio sensitizing, overcome chemoresistance | Prostate cancer, lung cancer, etc. |
|                      | Pioglitazone    | ↓Oxygen consumption | Antiproliferative, overcome chemoresistance | Prostate cancer |
| Antibiotics          | Tigecycline     | ↓mtDNA-encoded proteins, ↓Respiration | Overcome chemoresistance | Renal carcinoma, ovarian cancer |
|                      | Levofoxacin     | Mitochondrial dysfunction, oxidative damage | Inhibit proliferation, induce apoptosis | Lung cancer |
| Anthelmintic         | Niclosamide     | Mitochondrial dysfunction, activated Bax and caspases-3 | ↑Apoptosis, ↓Migration, ↓Invasion | Thyroid cancer, chondrosarcoma tumor |
|                      | Ivermectin      | ↓Mitochondrial respiration, ↓Membrane potential, ↓ATP levels | Inhibit angiogenesis, ↑growth and survival | Glioblastoma |
| Antimalarial agents  | Artemisinin     | ↓MMP, ↑ROS, ↑Ca2+ | Cell cycle arrest, ↑Apoptosis, Anti-angiogenesis | Colorectal cancer, breast cancer |
|                      | Artesunate      | Mitophagy, ↓GSH, ↑ROS | ↑Cell death | Cervical cancer |
| Antifungal agents    | Itraconazole    | VDAC1 inhibition, mitochondrial metabolism disruption | Inhibit angiogenesis, ↓Growth and survival | Breast cancer, liver cancer |
|                      | Ketoconazole    | Mitophagy | Antiproliferative, overcome chemoresistance | HCC |
|                      | Econazole       | Ca2+ channel inhibition, cytochrome c leakage | ↑Cell death, Anti-tumorigenesis | Leukemia, colorectal cancer |
| Antihypertension     | Prazosin        | ↓MMP, | Reduced tumor mass | Prostate |
|                      | Quercetin       | ↓MMP, | Antitumor, Radio sensitizing | Lung cancer, gastric cancer |
|                      | Lercanidipine   | Mitochondrial Ca2+ overload, mitochondrial vacuolation | ↑Apoptosis, chemosensitization | Breast cancer |
|                      | Telmisartan     | Mitochondrial fission, ROS accumulation | ↑Apoptosis, chemosensitization | Melanoma |
| Antidepressants      | Imipramine      | Stressed mitochondria restoration | Hijack aggressive character of cancer | Glioblastoma |
|                      | Amitriptyline   | Stressed mitochondria restoration | Hijack aggressive character of cancer | Glioma |
|                      | Chlorimipramine | ↓Complex III activity, ↓MMP, mitochondrial swelling and vacuolation | Antitumor | Glioma |
|                      | Fluoxetine      | Mitochondrial dysfunction | Antiproliferative, overcome chemoresistance | Colorectal cancer, breast, Ovarian cancer |
|                      | Depression      | Mitochondrial dysfunction | ↑Apoptosis, Antiproliferative, Pro-apoptotic, chemo sensitization | Bladder cancer |
|                      | Valproic acid   | ↓Respiration, ↓ATP production, ↑ROS | | Thoracic cancer, lung cancer, colorectal cancer |
the cellular redox status in HeLa cells [370]. In addition, atovaquone, another antimalarial agent, can inhibit mitochondrial complex III, thereby increasing the efficacy of radiotherapy [371].

Antifungal agents also play an important role in drug repositioning strategies for the treatment of various tumors [372–374]. Itraconazole is among the most well-studied broad spectrum antifungal agents for cancer treatment [374–378]. It has been reported that itraconazole can interact with mitochondrial protein VDAC1 and modulate the AMPK/mTOR signaling axis [379, 380]. Another study has demonstrated that itraconazole elicits apoptosis by altering MMP, reducing Bcl-2 expression and elevating caspase-3 activity [381]. Our group previously found that ketoconazole, a P450 inhibitor traditionally used for antifungal treatment [382], elicited PINK1/Parkin-mediated mitophagy and apoptosis, thereby suppressing HCC growth alone or synergistically with sorafenib [383]. In addition, Econazole (Eco), a potent agent used for tackling superficial mycosis, is now well recognized as an antagonist for store-operated Ca\(^{2+}\) channels to induce cell death of leukemia [384–386]. Expectedly, it has now been shown to trigger mitochondrial-mediated apoptosis and cause cytochrome c leakage and apoptosis-inducing factor (AIF) translocation [387].

In conclusion, repurposing of broadly antimicrobial compounds emerges as an important strategy to provide complementary and alternative first-line drugs for effectively targeting mitochondria in cancer cells. We believe that repositioning antimicrobial agents will be an important topic in realizing the reversion of cancer drug resistance by eliciting mitochondria-dependent apoptosis.

**Table 3 (continued)**

| Original application | Repurposed drug | Effects on mitochondria | Effects on cancer | Cancer type |
|----------------------|----------------|-------------------------|------------------|------------|
| Treatment for pain   | Aspirin        | Activated Bax and caspases-3, cytochrome c leakage | ↑Apoptosis        | Cervical cancer |
| Treatment for rheumatism | Indomethacin | Impairs mitochondrial dynamics | ↑Apoptosis, chemosensitization | Lung cancer, gastric cancer, etc. |
| Treatment for stomachache, abdominal pain, rheumatism | Auranofin | Inhibits mitochondrial TrxR | Antiproliferative | Lung cancer, ovarian carcinomas |
| Treatment for rheumatism, Liver cirrhosis | Angelica polymorpha root extract | ↓MMP, activated Bax and caspases-3 | ↑Apoptosis | Neuroblastoma |
| Treatment for thalassemia, Friedreich’s ataxia kidney disease | Euphorbia formosana Hayata (EF) | Mitochondria dysfunction | Tumor suppression | Leukemic cells |
| Treatment for thalassemia, Liver cirrhosis | Deferiprone | Suppress mitochondrial metabolism, ↓Respiration, ↑ROS | Antiproliferative, Reduce migration | Prostate, Breast cancer, etc. |
| Iron chelator | VLX600 | ↓Respiration, ↓ATP production | Antitumor, chemosensitization | Ovarian cancer, colorectal cancer, etc. |
| Copper overload disorder | Tetramethylthiourea | ↓Respiration, ↓ATP production | Inhibit angiogenesis, antitumor | Papillary thyroid cancer |
| Alcohol-aversion drug | Disulfiram | Mitochondrial fission, ↓MMP | Antitumor, chemosensitization | Melanoma, colorectal cancer |
| Copper-chelating agent | Elesclomol | Interacts with ETC, ↑ROS | ↑Apoptosis | Colorectal cancer, leukemia, etc. |
| Palliative effects | Cannabinoids | Mitochondrial damage, ↑ROS | Reduce proliferation, induce apoptosis and autophagy, Inhibit invasion and angiogenesis, Improve chemosensitivity | Oral cancer, Lung cancer, etc. |
caspase executing apoptotic pathways in PC-3 cells, thus significantly reducing tumor mass in PC-3-derived cancer xenografts [390]. Quercetin, a bioflavonoid with multiple activities including antihypertensive, and anti-inflammatory, has been repurposed for cancer treatment [391–393]. Accumulating studies have been devoted to exploring the molecular basis underlying the antitumor efficacy of quercetin. The decrease in MMP and subsequent apoptosis represent potential mechanisms [394–396]. Another antihypertensive drug, lecanidipine, was shown to induce apoptosis accompanied by severe vacuolation derived from the ER and mitochondria, thereby enhancing the cytotoxicity of various proteasome inhibitors, including bortezomib, carfilzomib, and ixazomib, in many solid tumor cells [397]. Furthermore, a widely used and safe antihypertensive drug, telmisartan, was suggested to alter cell bioenergetics by triggering mitochondrial fission and ROS accumulation, thereby sensitizing melanoma cells to treatment with vemurafenib [398].

Taken together, anti-cardiovascular disease drugs hold great potential to be endowed with novel characteristics to tackle tumors in a mitochondria-dependent way.

**Repositioning antidepressant drugs and anti-neurodegenerative drugs**

It has been increasingly recognized that antidepressant drugs exert anti-neoplastic properties, in addition to their well-documented ability to modulate neurotransmission [399–402]. Tricyclic antidepressants and their analogs are among the most well-studied repurposed drugs for cancer therapy. They have exhibited excellent efficacy in halting cancer cell growth and metastasis [403–406]. Interestingly, the antitumor efficacy of imipramine and amitriptyline primarily relies on their metabolic modulating ability in restoring the proper function of mitochondria, which differs from those functioning through disturbing mitochondria [407]. For instance, recent investigations showed that imipramine and amitriptyline restore stressed mitochondria and stimulate their function to hijack the aggressive character of cancer caused by mitochondrial dysfunction [408]. Chlorimipramine, another tricyclic antidepressant, has been shown to specifically inhibit mitochondrial CIII and cause decreased MMP as well as mitochondrial swelling and vacuolation, thus exhibiting a selective antitumor effect [409]. In addition, fluoxetine has been reported to increase doxorubicin accumulation within multiple drug-resistant (MDR) cells and inhibit drug efflux both in vivo and in vitro in resistant tumor models [410]. It is also able to induce mitochondria-mediated cell death in human epithelial ovarian cancer [411, 412]. Moreover, nortriptyline can induce both Fas, FasL, FADD axis-mediated extrinsic apoptosis and mitochondria dysfunction-triggered intrinsic apoptosis, thus suppressing bladder tumor growth in vivo [413].

Agents for treating neurodegenerative disease (such as Alzheimer’s and Epilepsy) have also been observed to be efficacious in the prevention and treatment of tumors [414, 415]. Valproic acid (VPA), an antiepileptic drug, has been shown to inhibit class I HDAC and exert antiproliferative, pro-apoptotic, and chemosensitizing effects in human lung cancer and colorectal cancer by restraining the cell cycle and eliciting ROS generation [416, 417]. In addition, VPA significantly induced mitochondrial dysfunction, thus reducing respiration and ATP production causing mitochondria-dependent apoptosis, which potentiated TRAIL-mediated cytotoxicity on cultured thoracic cancer and HCC cells [418, 419].

**Repositioning anti-inflammatory and antirheumatic drugs**

Nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., indomethacin, ibuprofen, aspirin, and diclofenac) are the most commonly prescribed compounds for treating pain and inflammation [420–422]. It is widely accepted that NSAIDs possess anti-neoplastic effects in a wide spectrum of cancers [423–426]. In fact, prolonged NSAID administration reduces the risk of developing tumors [427, 428], and these non-oncology drugs are now applied to combination therapeutic regimens to potentiate the efficacy of chemotherapy and radiotherapy [429]. Based on the inhibitory effect on prostaglandin-synthesizing cyclooxyge nases 1 and 2 (COX-1/2) and the role of nonsteroidal anti-inflammatory drug-induced gene NAG-1 in initiating the intrinsic apoptosis pathway [430], the mechanism of action underlying their antitumor efficacy is strongly related to mitochondrial dysfunction and ROS production caused by inhibition of mitochondrial respiration [431, 432]. This is best exemplified by aspirin, an FDA-approved NSAID for the treatment of pain and fever [433, 434]. Studies focusing on its antitumor mechanisms revealed that aspirin causes cytochrome c leakage and induces caspase-dependent apoptosis in cancer cells [435]. This mitochondrial damage is also probably responsible for the circumvention of resistance and sensitization to cisplatin by asplatin, a Ptd(IV) produg of cisplatin, due to the ligation of aspirin [436]. Indomethacin, another NSAID initially used for treating rheumatic disease, has been found to induce mitochondria-mediated apoptosis in doxorubicin-resistant lung cancer cells through an MRP1-dependent mechanism [437]. In addition, indomethacin can activate the PKCζ-p38-DRP1 pathway to impair mitochondrial dynamics, thus inducing apoptosis in gastric cancer [438].

Other groups of anti-inflammatory and/or antirheumatic drugs also exhibit antitumor efficacy. Auranofin, an inhibitor of thioredoxin reductase (TrxR) initially
developed for the treatment of rheumatoid arthritis, exhibited anticancer activity against various tumor types. It was approved for clinical trials in lung and ovarian carcinomas [439–443]. Further investigations revealed that auranofin targets both the cytosolic and mitochondrial forms of TrxR, indicating that mitochondrial alterations might participate in the inhibitory effect of auranofin on cancer [444, 445]. In addition, Euphorbia formosana Hayata (EF), a Taiwanese medicinal plant for the treatment of rheumatism, has been repurposed for tumor suppression by eliciting apoptosis via the Fas and mitochondrial pathways in leukemic cells [446].

In summary, anti-inflammatory agents, pain-relieving medication, and antirheumatic drugs are now documented to be effective again diverse critical disorders including cancer, for which mitochondrial-related mechanisms are well recognized to be involved in their antitumor effects.

**Repositioning ion chelating agents**

Ion chelating agents represent a category of effective antitumor agents by targeting mitochondria, as mitochondria use metals (such as iron, copper, calcium, zinc) for the synthesis of cofactors of oxidation–reduction enzymes [447]. Deferiprone (DFP), an iron chelator used clinically in thalassemia, kidney disease, and Friedreich's ataxia, has been identified to reduce the proliferation and migration of cancer cells [448, 449]. The underlying mechanisms are well documented to involve the suppression of mitochondrial metabolism and the respiration rate, as well as induction of ROS production [450, 451]. VLX600, a recently designed iron chelator, has been characterized as a mitochondrial OXPHOS inhibitor which exhibited outstanding antitumor ability ovarian and breast and colorectal cancers [452–454]. Intriguingly, VLX600 was reported to inhibit mitochondrial respiration and augment the efficacy of imatinib in gastrointestinal stromal tumors [455]. It has also been suggested to sensitize ovarian cancer cells to platinum agents and PARPis (two standard-of-care therapies) [456].

Another metal with important functions in cancer progression is copper. Tetrathiomolybdate, a copper-chelating drug used in the treatment of copper overload disorder, has also shown obvious antitumor effects. Besides reducing angiogenesis, it can impair mitochondrial respiration as well as ATP production mainly by inhibiting copper-dependent mitochondrial C IV activity [457, 458]. In recent decades, disulfiram, the alcohol-aversion drug which functions in a copper complex to treat alcohol abuse [459], has attracted considerable attention for its alone or synergistic anticancer activity [460–465]. It functions as a disulfiram-Cu$^{2+}$ complex (DSF-Cu$^{+}$/Cu$^{2+}$) to induce mitochondrial fission and reduce MMP, thus suppressing tumors via a redox-related apoptosis process [466]. In addition, elesclomol exerts potent anticancer activity by inducing oxidative stress and apoptosis [467–471]. Mechanistically, elesclomol forms an elesclomol-Cu (II) complex by chelating copper (Cu) outside of cells, which rapidly transports copper into the mitochondria, thus inducing mitochondrial ROS accumulation [472, 473]. Other types of metal chelators, including zinc and calcium chelating agents, have also been recognized as effective antitumor agents [474, 475].

Additionally, there are other compounds that do not belong to the groups discussed above which could be repurposed for cancer therapy via mitochondrial-mediated mechanisms. For instance, besides the palliative effects, cannabinoids and their analogs have shown promise as antitumor agents to reduce proliferation, induce apoptosis and autophagy, inhibit invasion and angiogenesis, and improve chemosensitivity to anticancer drugs [476]. Unequivocally, cannabinoids have been demonstrated to disrupt mitochondria damage and trigger ROS production both in human primary tumors and those resistant to chemotherapeutic drugs [477–479]. Furthermore, many commonly used chemotherapeutic drugs have been proven to interfere with mitochondria to promote anticancer effects, including, but not limited to, cisplatin [480, 481], doxorubicin [482, 483], sorafenib [484], and tamoxifen [485]. This broad variety of agents provide a plethora of options for tumor therapy by targeting mitochondria. We believe that targeted delivery of these drugs to mitochondria could benefit cancer treatment and overcome drug resistance.

In summary, repurposing non-oncology drugs is considered as an effective strategy to alleviate the current lack of mitochondria-targeting drugs. It holds the potential to develop effective agents in a short time period with lower development costs. However, it is not trivial to successfully apply suitable non-oncology drugs as anticancer therapeutics. Assessment of their effectiveness and understanding the underlying mechanistic in preclinical models are critical.

**Mitochondria-targeted drug delivery system and multifunctional strategy**

In recent years, organelle-specific delivery of bioactive molecules has been widely utilized for cancer treatment to achieve high selectivity, maximum therapeutic effects, minimum side effects, and minor resistance [486–490]. Mitochondria-targeting therapeutic strategies can directly affect the mitochondrial membrane or matrix, mitochondrial metabolism, and the mitochondrial apoptosis or regulatory signaling pathways [306, 491–494]. Researchers have developed or identified a
number of mitochondria-targeted drug delivery systems (MTDDs), with most of them currently transporting chemotherapeutics into the mitochondria based on the high membrane potential across the inner mitochondrial membrane or the mitochondrial protein import machinery [495–498]. The following section will provide insights into the application of novel mitochondria-targeting strategies for cancer therapy (Table 4).

### Mitochondrial protein import machinery-based targeting strategies

Except for a small number of mitochondria-encoded factors (e.g., key proteins in the ETC, rRNAs, tRNAs), the vast majority of proteins present in the mitochondria are encoded by the nucleus and translocated from the cytosol [499–503]. Transporting machinery protein complexes (e.g., TIM/TOM complex) recognize and transport these proteins from the cytoplasm to the mitochondria, where proteins with mitochondria-targeting signal peptides (MTSs) are escorted from the cytosol to mitochondrial outer membrane [504, 505]. MTSs always exhibit positive charge and easily form amphiphilic α-helices and thus have been successfully used for the selective and effective delivery of therapeutics to mitochondria for disease treatment, including cancer therapy [506]. In addition, MTSs conjugate to, and deliver, a variety of cargo molecules (e.g., proteins, nucleic acids). For instance, p53-BakMTS/p53-Bax were synthesized via fusing p53 or its DNA-binding domain (DBD) to MTSs from Bak or Bax by Matissek et al. This regiment is capable of targeting p53 to the mitochondria and executing mitochondria-mediated apoptosis in cancers [507]. Several mitochondria-targeting units take advantage of the IMM-embedded transporters. For example, a self-assembled protein nanoparticle named GST-MT-3(Co$^{2+}$) NPs was prepared by Zhu et al., via covalently conjugating paclitaxel to GST-MT-3(Co$^{2+}$), to specifically target mitochondria. Co$^{2+}$ in the NPs depolarized the MMP and elevated ROS, which subsequently induced apoptosis to execute antitumor effects. Intriguingly, this nanoparticle exhibited a synergistic effect manifesting as 50-fold lower paclitaxel dosage which possessed a highly effective antitumor effect [508]. Similarly, a functional hybrid peptide (MTS-R8H3) was used to prepare a modified targeted liposome, DOX/CEL-MTS-R8H3 lipo, for codelivery of doxorubicin hydrochloride (DOX) and celecoxib (CEL) [509]. This liposome codelivery system exhibited remarkable treatment efficacy on killing DOX-resistant MCF-7 (MCF-7/ADR) cells, providing a promising strategy for overcoming drug resistance in breast cancer.

### Cell-penetrating peptide-based mitochondria-targeting strategies

Cell-penetrating peptides (CPPs) are nontoxic, short, cationic, and/or amphipathic peptides able to directly cross the cellular membrane [510–512]. They serve as a popular and efficient vector for delivering a broad variety of cargoes, including oligonucleotides, proteins, and therapeutics [513–515]. Many efforts are being made to improve their cell specificity for selective uptake by tumor cells, permitting medical applications [516–518]. Modifying the CPPs according to microenvironment condition is a widely used strategy. Particularly, mitochondria-penetrating peptides (MPPs) have been developed to deliver a variety of antitumor cargoes into mitochondria, which can inhibit tumor growth in vivo and in vitro [519–522]. For example, Dox was intercalated into the Cyt c aptamer contained DNA duplex and subsequently loaded in the dendrigraftpoly-L-lysines (DGL) and combine to cyclopeptide RA-V contained pH-sensitive liposomal shells, for preparing a MPP-modified DGLipo NPs. This system could successively deliver both DOX and RA-V into lysosome and mitochondria of cancer cells, and achieved a spatiotemporally controlled release of them to monitor cytochrome c release and apoptotic process, leading to enhanced therapeutic outcomes in MDR tumors [462]. In addition, the TAT-PEG-DOPE system (methoxy poly(ethylene glycol)-2000–1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine (mPEG-DOPE) and transactivator of transcription (TAT) peptide conjugated PEG-DOPE) is an example, in which sulfonamide will lose charge and detach when it suffers a decrease in pH, so that exposed TAT can interact and take the drug-loaded micelles to selectively kill tumor cells [523]. Several other novel CPPs for targeting cancer cell mitochondria, including Pal-pHK-pKV, an engineered peptide performed with the N-terminus of the HK-II protein [524]; pHK-PAS, achieved by covalently coupling N-terminal 15 aa of HKII (pHK) to a short, penetration-accelerating sequence (PAS) [525]; MTP3, another engineered peptide synthesized via resin-based solid-phase peptide synthesis, are also serving as efficient tools to deliver exogenous therapeutics into mitochondria and representing promising strategy in cancer therapy.

### Delocalized lipophilic cation (DLC)-based mitochondria-targeting strategies

It has been well demonstrated that the MMPs of tumor cells are usually higher than that of non-malignant cells [526–528]. The hydrophobic surface areas and delocalized positive charge of DLCs permit them to rapidly pass through membrane bilayers and accumulate in cancer cells because of the more negative MMPs in cancer cells [529–532]. This offers a selective drug delivery approach
Table 4: Representative mitochondria-targeting therapeutic regimens

| Mitochondria-targeted machinery | Mitochondria-targeted delivery method | Therapeutic regimens | Molecular mechanisms | Effects on cancer | Ref |
|--------------------------------|--------------------------------------|----------------------|---------------------|------------------|-----|
| Mitochondrial protein import machinery | Mitochondria-targeting signal peptides | M-ChiP | ROS production | Necrosis, enhanced therapeutic effect with reduced side effect | [580] |
| | | AuNR@MSN-ICG-β-CD/Ada-RLA/CS (DMA)-PEG | ROS production, local hyperthermia | Enhanced antitumor effect with minimal side effect | [581] |
| | | p53-BakMTS (or BaxMTS) and DBD-BakMTS (or BaxMTS) | Activation of MOMP and caspase-9 | Apoptosis | [507] |
| | | DOX/CEL-MTS-R8H3 | ROS production; inhibition of P-gp efflux activity | Overcoming drug resistance in breast cancer | [509] |
| Protein nanoparticle | GST-MT-3(Co2+) NPs | ROS production, reduction of MMPs | Suppressing tumors and prolonging survival | [508] |
| Cell-penetrating peptide-based | Cell-penetrating peptide | Pal-pHK-pKV NPs | Targeting the VDAC1-hexokinase-II complex | Amplifying lung cancer cell death | [524] |
| | | DGLipo NPs | ROS production | Overcoming multidrug resistance | [582] |
| | | TAT-PEG-DOPE system | / | Selectively killing tumor cells | [523] |
| | | pHK-PAS | Cytochrome c release; disruption of the mitochondria-HKII association | Apoptosis | [525] |
| | MTP3 | Mitochondrion-targeting prodrg (compound 17, doxorubicin-based prodrg) | Mitochondrial depolarization | Enhanced cytotoxicity against human tumor cells while negligible toxicity toward normal cells | [583] |
| Delocalized lipophilic cation (DLC)-based | Triphenylphosphonium (TPP)-based | TPP-LND-DOX NPs | Apoptosis | Conquering drug resistance | [243] |
| | | TPP-PEG-L | Apoptosis | Enhancing paclitaxel-induced cytotoxicity and antitumor efficacy | [540] |
| | | TPGS1000-TPP-Targeting paclitaxel liposomes | Apoptosis | Inhibiting drug-resistant lung cancer | [541] |
| | | THMSNs@LMDI | Singlet oxygen generation | Sensitizing A549/MCF-7 cells to doxorubicin | [578] |
| | | Fe3O4@Dev/TPP/PpIX/ss-mPEG | Fenton reaction | Improving antitumor therapeutic efficacy | [574] |
| | Dequalinium (DQA) | TPP-PF127-HA | Cytochrome c release; activation of caspase-3 and caspase-9 | Eradicating drug-resistant of lung cancer | [497] |
| | | Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes | Activation of caspase-9 and caspase-3 | Treating invasive breast cancer | [584] |
| | Metal complexes | DQA-PG2000-DSPE | Apoptosis | Enhancing the anticancer efficacy against cisplatin-resistant A549 cells | [545] |
| | | DQA and folate-loaded functional DOX nanoparticles | Activation of caspase-9 and caspase-3 cascade | Overcoming multidrug-resistant cancers | [546] |
| | Guanidinium | BZ@TPY, PPY, THPY | ROS elevation | Killing cancer cells effectively even under hypoxic conditions | [585] |

Jin et al. Journal of Hematology & Oncology (2022) 15:97
| Mitochondria-targeted machinery | Mitochondria-targeted delivery method | Therapeutic regimens | Molecular mechanisms | Effects on cancer | Ref |
|---------------------------------|--------------------------------------|----------------------|----------------------|------------------|-----|
| Synthetic secretion system in *E. coli* | T3SS | enT3SS | Cytotoxic activity | Eliminating tumors and reducing the mortality of tumor-bearing animals | [553] |
| Others | Coumarin | Bromocoumarin platinum 1 ZIF-90@DDP | p53 apoptosis pathway / | Overcoming cisplatin resistance Overcoming platinum-resistant ovarian cancer | [556] [557] |
| Berberine (BBR) | Paclitaxel (PTX)-ss-BBR | ROS production; G2/M arrest | Enhancing the effect of CT in A549 cells | [587] |
| d-(KLAKLAK)_{2} | d-(KLAKLAK)_{2} | Cytochrome c release Apoptosis; Modulation of lipid metabolism | Enhancing the anticancer efficacy Enhanced bioavailability; Against multiple cancer stem cells Sensitizing cancer cells to cisplatin | [588] [589] [319, 590] |
| Ion-pair stabilized lipid matrix | Bio-nFeR | | | |
| Enzymatic self-assembly | Enzymatic cleavage of branched peptides | Flag-(C16)_{2} - CLRP | Inhibition of the mitochondrial protein synthesis; Cytochrome c release | | [319, 590] |
to deliver compounds to tumors with little toxicity to normal healthy cells.

While Rhodamin123 was the first DLC identified to markedly inhibit the growth of carcinoma cell lines and prolong the survival of tumor-bearing mice [533, 534], the triphenylphosphonium (TPP) cation is the most well-documented DLC that has been used for mitochondria targeting [346, 495, 535]. TPP⁺ cations were conjugated to a wide variety of synthesized residues and incorporated into the liposomal lipid bilayer to make drug delivery systems for mitochondria targeting and tumor suppression [536–539]. For example, Biswas et al. synthesized a polyethylene glycol-phosphatidylethanolamine (PEG-PE) and TPP⁺ group modified liposomes (TPP-PEG-L). TPP-PEG-L has been demonstrated to enhance paclitaxel-induced cytotoxicity and antitumor efficacy compared to plain liposomes (PL) from efficient mitochondria targeting [540]. In addition, a D-α-tocopheryl polyethylene glycol-1000 succinate-tri phenylphosphine (TPGS1000-TPP) was incorporated onto the surface of paclitaxel liposomes to prepare TPGS1000-TPP conjugate. This regimen could selectively accumulate into the mitochondria and initiate caspase-9- and caspase-3-mediated apoptosis, thereby exhibiting significant antitumor efficacy in drug-resistant A549/cDDP xenograft and cells [541].

Dequalinium chloride (DQA) has been regarded as a new class of anti-carcinoma agents based on its selective localization and accumulation within the mitochondria of cancer cells [542–544]. For example, a dequalinium polyethylene glycol-distearoylphosphatidyl-dy lethanolamine (DQA-PEG2000-DSPE) conjugate was synthesized to develop mitochondrial-targeted resveratrol liposomes to overcome drug resistance. This mitochondrial-targeted liposome is significantly accumulated in the mitochondria and induces apoptosis in both nonresistant and resistant cancer cells by dissipating MMPs. In addition, cotreating this liposome with vinorelbine liposomes remarkably enhanced the anticancer efficacy against cisplatin-resistant A549 cells [545]. Furthermore, functional nanoparticles based on DQA were developed for targeted delivery of classical cytotoxic anticancer drugs (such as doxorubicin) to tumor cells, which showed significant anticancer efficacy in a drug-resistant tumor model via triggering cytochrome c release and mitochondrial apoptosis [546].

**Newly developed mitochondria-targeting units-based strategies**

In recent years, numerous drug delivery systems, including liposomes, micelles, “smart” polymers, and hydrogels, have been developed for cancer therapy [547–552]. For instance, to achieve accurate delivery to mitochondria with high specificity and low size, a native genetic system encoded in Salmonella pathogenicity island-1 (SPI-1) was used by Lim et al. [553]. In their study, *E. coli* carrying synthetic T3SS and MTD on plasmids could eliminate tumors and reduce the mortality of tumor-bearing animals. Furthermore, another study developed a perimitochondrial enzymatic self-assembly system to deliver chloramphenicol (CLRP) to the mitochondria in cancer cells. Importantly, their results suggested that this new system could overcome cisplatin resistance by inhibiting the synthesis of mitochondrial proteins.

Modifying traditional drugs with newly developed mitochondria-targeting units also exhibited potential to reduce side effects and reverse drug resistance to some extent [554, 555]. For instance, Ma et al. designed bro mocoumarin platinum 1 therapeutic (a coumarin-Pt (IV) prodrug) to simultaneously target mitochondria and nuclei [556]. This therapy allows simultaneous accumulation of high concentrations of Pt in both the nDNA and mtDNA, thus triggering apoptosis to overcome cisplatin resistance. Moreover, p53 activation promoted Pt–DNA-induced apoptosis in cancer cells, leading to obvious anticancer activity with this prodrug. In addition, Xing and co-workers synthesized a mitochondria-targeting zeolitic imidazole framework loaded with platinum (ZIF-90@DDP) to kill cancer cells by promoting effective drug release under specific pH and ATP levels, thus providing a new strategy for reversing platinum resistance in ovarian cancer [557].

**Multifunctional drug delivery strategies**

At present, mitochondria-targeting photothermal therapy (PTT), photodynamic therapy (PDT), chemo-dynamic therapy (CDT), and related combinational therapies have attracted global attention due to their advantages of a wide therapeutic range, minimal toxicity, excellent safety profile, noninvasiveness, and low drug resistance [558–560]. PTT triggers thermal damage by conversing light energy into heat to kill cancer cells [561–563]. In recent years, a variety of photothermal materials, including inorganic nanomaterials (such as gold nanocages, gold nanorods, and other gold nanostructures), transition metal sulfide or oxide nanoparticles, have been developed to improve the energy conversion from near infrared (NIR) light [564, 565]. As such, PTT has shown remarkable achievements in the treatment of various tumors [566–569]. PDT is available for treating a broad variety of cancers through local ROS production only in the light-exposed region by utilizing photosensitizer (PS), light, and oxygen [570–573]. Recently, Fe₃O₄@Dex-TPP nanoparticles have been prepared by coprecipitation in TPP-grafted dextran (Dex-TPP) and Fe²⁺/Fe³⁺ and then incorporated with the photosensitizers of
protoporphyrin IX (PpIX) and glutathione-responsive mPEG-ss-COOH to form a fenton reaction-assisted PDT, noted Fe3O4@Dex/TPP/PpIX/ss-mPEG nanoparticles [574]. This nanoparticle targets mitochondria by photoinduced internalization, leading to ROS generation and the fenton reaction-produced O2, thus significantly improving the therapeutic efficacy on tumor. In addition, Zeng et al. synthesized bifunctional nanoprobe (FA-NPs-DOX) by loading DOX to NaYF4:Yb/Tm-TiO2 inorganic photosensitizers for in vivo inorganic PDT [575]. In this study, folic acid (FA) targeting and NIR-triggered inorganic PDT accelerated the release of DOX and promoted the inhibition rate in drug-sensitive MCF-7 and resistant MCF-7/ADR cells.

In addition, other therapies, including CDT [576, 577], sonodynamic therapy (SDT), gas therapy, radiation therapy (RT), alone or in combination with other treatments targeting mitochondria to inhibit tumors, are emerging, as described in a comprehensive review [491]. For instance, Shi et al. designed a mitochondria-targeted hollow mesoporous silica nanoparticles (THMSNs) loaded with L-menthol (LM) to carry DOX and NIR dye indocyanine green (ICG), named THMSNs@LMDI [578]. Under NIR irradiation, this system simultaneously produces photodynamic and photothermal therapy effect via DOX release and apoptosis activation, thereby sensitizing A549/MCF-7 cells to DOX. Intriguingly, a specific targeting of mitochondria and imaging-guided chemophotothermal therapy against cisplatin resistance was proposed by Yang and colleagues [579]. In this work, Pt (IV)-NPs, a nanoparticle precisely assembled by biotin-labeled Pt (IV) prodrug derivative and cyclodextrin-functionalized IR780, integrated with targeting units, imaging moieties into a single regimen to overcome and even completely eliminate cisplatin resistance A549R tumors, thus providing a beneficial precise therapeutic. Undoubtedly, combination therapies achieve synergistic effect of anticancer and hold more beneficial for future clinical translation.

In summary, the development of mitochondria-targeting units and combinational strategies for cancer therapy has achieved precise treatment at lower drug doses (Table 4), offering excellent prospects for improving the therapeutic effect and overcoming drug resistance.

**Therapeutic applications of mitochondrial transplantation**

The transplantation of mitochondria from healthy cells to abnormal cells has emerged as a novel and attractive therapeutic strategy to treat diseases caused by mitochondria damage or dysfunction [591–595]. While intercellular mitochondrial transfer functions as essential stress-adaptive mechanism to endow cancer cells with resistance to chemotherapy [175, 176], mitochondrial transplantation (mTTP) has been used in preclinical and clinical studies to restore mitochondrial function for cancer therapy and eliminate drug resistance [596–599]. For example, Chang et al. transferred mitochondria into breast cancer cell lines [321]. The results suggested that mitochondria transplantation-induced cell apoptosis inhibited cell growth and decreased oxidative stress, thereby increasing the susceptibility of both MCF-7 and MDA-MB-231 breast cancer cells to doxorubicin and paclitaxel. In addition, intercellular endocytosis (e.g., mitochondria internalization) was suggested to enhance the TCA cycle and aerobic respiration, attenuate glycolysis, and reactivate the mitochondrial apoptotic pathway, thereby inhibiting malignant proliferation and enhancing the radiosensitivity of gliomas in vitro and in vivo [600].

Overall, mTTP appears to be a very promising therapeutic option to fine-tune mitochondria function in cancer cells so that drug resistance might be overcome. However, research on mitochondrial transplantation for cancer treatment is still in its infancy. Further investigations including preclinical and clinical studies are required to determine if it is effective in sensitizing cancer cells to radio- or chemotherapy. Additionally, various technical and ethical issues need to be addressed before its actual clinical application.

**Conclusions and perspectives**

Mitochondria are crucial players in cancer cell survival, as they are the bioenergetic and biosynthetic hub that coordinates cellular respiration, FAO, the TCA cycle, ETC, Ca2+ signaling, and redox homeostasis. Cancer drug resistance, as an adaptive strategy employed by cancer cells to survive stress conditions, is inevitably associated with mitochondrial-related pathways [62, 82, 601]. In fact, emerging evidence strongly indicates that resistant tumor cells exhibit high mitochondrial respiration and OXPHOS status [602, 603]. Therefore, targeting mitochondria represents a promising cancer treatment avenue and chemoresistance overcoming strategy. In this review, we have elaborated on the mechanisms of mitochondrial dynamics in number, structure, and location to maintaining mitochondrial function to endow cancer cells with metabolic flexibility for adapting to stress conditions, with an emphasis on their regulatory role in drug resistance. We have also summarized recent advances that focus on developing therapeutics that specifically target the mitochondria for cancer therapy. Notably, two representative compounds, metformin and CPI-613, have been taken on to phase III clinical trials (Table 2). Lastly, we have highlighted the repurposing of “old” drugs for mitochondria targeting in tumor therapy with the potential to effectively kill tumors. The development of mitochondria-targeting approaches will undisputedly...
boost the precision of cancer treatment at lower drug doses (Fig. 4, Table 5).

It is worth noting that further investigations are urgently needed to handle several key mitochondrial-related questions for their successful application in clinic cancer treatment. First, it will be pivotal to identify additional molecular mechanisms that cause the high OXPHOS status of cancer cells. It is also important to explore the roles and mechanisms of metabolic advantages in maintaining this high OXPHOS activity and how they modulate resistance to targeted or chemotherapies, as mitochondria are the hub of many metabolic pathways. Second, the roles of mitochondrial reshaping, rebuilding, and recycling are largely in a context-dependent manner, which remain vastly unexplored. Further study focusing on developing rational targeted approaches to modulate adaptive response will definitely require the possibility to accurately map dynamic processes and monitor bioenergetic and metabolic changes over a considerable time period [621]. Theoretically, drug repurposing and systematic screening approaches as well as advanced bioinformatics could replenish the inventory of antitumor drugs and break one of the current bottlenecks of drug development. However, it is important to decipher their mechanism of action and identify patients who would benefit from treatment with these compounds. In addition, more preclinical studies and clinical trials must be completed before such interventions become common practice in cancer therapy.

Modification of traditional therapeutics with mitochondria-targeting units has potential for reducing drug resistance and adverse side effects. Many of these strategies have been applied as preclinical or clinical antitumor therapies. However, safety evaluation based on biocompatibilities, release, accumulation, and metabolism is a prerequisite for their application. Indeed, limitations in the materials, such as toxicities and poor drug loadings, have restricted the further application of multifunctional nanodrugs. Future pharmaceutical research should focus on addressing the aspects mentioned above while exploring new materials. Notably, these therapeutics need to overcome both physiological and biological barriers before localizing to their target sites to take effect. What happens in these processes will affect the release of drugs and affect their antitumor efficacy. Therefore, it is important to endow the delivery system with some specific related functions. In addition to structural reformation, future research needs to investigate the mechanisms of exerting treatment, especially at the molecular level.

In the coming years, we predict that advances in omics technology, PET imaging combined with cancer genomics, will help a timely elucidation of metabolic
Table 5 Overview of mitochondria-targeting strategies for cancer treatment

| Mitochondria-targeting strategies       | Description                                                                                                                                                                                                 | Compositions                                                                 | Characteristics                                                                                           | Refs.       |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|-------------|
| Conventional chemotherapy              | A promising strategy that directly acts on mitochondria to produce toxic substances to cells and induces cancer cell death by endogenous chemical energy without the stimulation of external light sources | CT drugs (Betulinic Acid, Resveratrol, Ditercalinium Chloride, Benzo-α-pyrene (coumarin), α-TOS, Organic Arsenicals) | Easy to penetrate mitochondrial membrane and target mitochondria due to high lipid solubility; high effectiveness of tumor treatment | [556, 604, 605] |
| Nanoplatform loaded with CT/RT drugs   | CT/RT drugs are modified by mitochondria-targeting units or designed as nanoplatforms for cancer treatment                                                                                               | CT/RT drugs (Lonidamine, Paclitaxel, Doxorubicin, Cisplatin); mitochondria-targeting units | High effectiveness of tumor treatment                                                                    | [557, 587, 606] |
| CDT                                    | A burgeoning therapy through undergoing a fenton reaction or a fenton-like reaction, which reacts with excessive intracellular hydrogen peroxide (H₂O₂) in tumor tissues to generate hydroxyl radicals (·OH) | CT drugs; mitochondria-targeting units                                   | Low invasiveness; consumption of endogenous H₂O₂ without external energy; little normal tissue toxicity     | [576, 577]   |
| PTT                                    | Killing cancer cells with thermal damage (conversion of light energy into heat) utilizing an external light source (usually near-infrared (NIR) light) and photothermal agent as heat-generating source; PTT has strong absorption characteristics for NIR | Photothermal materials, external light source; mitochondria-targeting unit | Deep penetration and minimal damage to surrounding healthy tissue; noninvasiveness; Minimal side effects; temporal and spatial selectivity | [567, 607, 608] |
| PDT                                    | A locally targeted therapy utilizing a photosensitizer (PS), light, and oxygen to selectively kill tumors                                                                                               | PS, light, oxygen, seryl lipophilic, and cationic groups                  | Accurate controllability; minimal drug resistance                                                       | [562, 570, 572] |
| RT-RDT                                 | Stimulating PS to produce 1O₂ to kill tumors under ionizing radiation                                                                                                                                       | PS, 1O₂ and mitochondria-targeting unit                                  | Reach deeper tissues; low dosage possessing effective therapeutic effect                                  | [609, 610]   |
| SDT                                    | To kill cancer cells by stimulating exogenous (ultrasound) to activate SDT agents for producing ROS, cavitation, air bubbles, and hyperthermia                                                              | Ultrasound, SDT agents, ROS, cavitation, air bubbles, and hyperthermia    | Depth of tumor tissues can be realized by ultrasound; Achievement of noninvasive treatment; high precision of target lesion zones | [611]        |
| Gene therapy                           | Replacement of defective genes by delivering wild-type ones into the host cell, or silencing a dominant mutant allele that is pathogenic to address mitochondrial diseases,                                          | Therapeutic cargoes; delivery system                                     | Precision treatment                                                                                      | [612–614]   |
| Gas therapy                            | Using gaseous molecules to combat cancer                                                                                                                                                                    | Gaseous molecules such as nitric oxide, CO, hydrogen sulfide, and hydrogen; mitochondria-targeting unit | Noninvasive in situ treatment with no depth limit                                                      | [615, 616]   |
| Combination therapy                    | Combination of CT and PTT, CT and CDT, PDT and PTT, PDT and CDT, PDT and CT; PDT and Immunotherapy                                                                                                         | /                                                                          | Achieve synergistic effect of anticancer; minimize multidrug resistance; reduced pain in patients       | [579, 617–620] |
vulnerabilities and lead to the recognition of rational combinations of mitochondria-targeting inhibitors with standard treatments, which will hopefully bring new and more effective strategies for cancer therapy and drug resistance management (Fig. 5) supporting precision/personalized medicine.

Fig. 5 Rational design for targeting mitochondria in cancer therapy. Drug repurposing, mitochondrial-targeted nanomedicines, and mitochondrial transplantation represent opportunity to offer promising strategies for targeting mitochondria to overcome cancer drug resistance. The mitochondrial inhibitors may be used in combination with chemotherapy, radiotherapy, or even immunotherapy to provide new avenues for cancer therapeutic regimes.
Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
All authors have read and approved the final manuscript.

Competing interests
The authors declared no potential competing interests.

Author details
1 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital and West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University and Collaborative Innovation Center for Biotherapy, Chengdu 610041, People’s Republic of China. 2 Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia. 3 Guangdong Provincial Key Laboratory of Regional Immunity and Diseases, Department of Pharmacology and International Cancer Center, Shenzhen University Health Science Center, Shenzhen 518060, Guangdong, People’s Republic of China. 2 Department of Biochemistry and Molecular Biology, Monash University, Clayton, VIC 3800, Australia.

References
1. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–26.
2. Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20:398–411.
3. Hanker AB, Sudhan DR, Arteaga CL. Overcoming endocrine resistance in breast cancer. Cancer Cell. 2020;37:496–513.
4. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med. 2002;53:615–27.
5. Marine J-C, Dawson S-J, Dawson MA. Non-genetic mechanisms of therapeutic resistance in cancer. Nat Rev Cancer. 2020;20:743–56.
6. Braun TP, Eide CA, Druker BJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell. 2020;37:530–42.
7. Jiang J, Zhang L, Chen H, Lei Y, Zhang Y, Wang Y, Jin P, Lan J, Zhou L, Huang Z, et al. Regorafenib induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma. Autophagy. 2020;16:106–22.
8. Zhang Z, Qin S, Chen Y, Zhou L, Yang M, Tang Y, Zuo J, Zhang J, Mizolami A, Nice EC, Chen HN, Huang C, Wei X. Inhibition of NPC1-L1 disrupts adaptive responses of drug-tolerant persistir cells to chemotherapy. EMBO Mol Med. 2022;14(2):e14903.
9. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resistance Updates. 2011;14:191–201.
10. Boulou JC, Yousof Idris MR, Effert T. Investigation of cancer drug resistance mechanisms by phosphoproteomics. Pharmacol Res. 2020;160:105091.
11. Li B, Jiang J, Assaraf YG, Xiao H, Chen Z-S, Huang C. Surmounting cancer drug resistance: new insights from the perspective of N-methyladenosine RNA modification. Drug Resistance updates. 2020;53:100720.
12. Jin P, Jiang J, Xie N, Zhou L, Huang Z, Zhang L, Qin S, Fu S, Peng L, Gao W, et al. MCT1 relieves osimertinib-induced CRC suppression by promoting autophagy through the LKB1/AMPK signaling. Cell Death Dis. 2019;10:615.
13. Gong K, Guo G, Gerber DE, Gao B, Peyton M, Huang C, Minna JD, Hatanpaa KJ, Karnitz KL, Kernstine K, Cai L, et al. TGF-β-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. J Clin Invest. 2018;128:2500–18.
14. Eritja N, Chen B-J, Rodríguez-Barrueco R, Santacana M, Gatisus S, Vidal A, Martí MD, Ponce J, Bergadá L, Yermian A, et al. Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy. 2017;13:608–24.
15. Ghosh JC, Siegelin MD, Vaira V, Faversani A, Tavecchio M, Chae YC, Lisanti S, Rampini P, Girota M, Cairo MC, et al. Adaptive mitochondrial reprogramming and resistance to PI3Kd therapy. J Natl Cancer Inst. 2015;107.
16. Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5:8.
17. Payandeh Z, Pippour Tazehkand A, Barati G, Pouremamali F, Kahoea H, Baradarab B, Samadi N. Role of Nrf2 and mitochondria in cancer stem cells; in carcinogenesis, tumor progression, and chemoresistance. Biochimie. 2020;179:32–45.
18. Qin S, Li B, Ming H, Nice EC, Zou B, Huang C. Harnessing redox signaling to overcome therapeutic-resistant cancer dormancy. Biochimica et Biophysica Acta (BBA) - Rev Cancer. 2022;1877(4):188749.
19. Li B, Huang Y, Ming H, Nice EC, Xian R, Huang C. Redox Control of the Dormant Cancer Cell Life Cycle. Cells. 2021;10(10):2707.
20. Smith RL, Soeters MR, Wust RCJ, Houtkooper RH. Metabolic flexibility as an adaptation to energy resources and requirements in health and disease. Endocr Rev. 2018;39;489–517.
21. Boumahdi S, de Sauvage FJ. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat Rev Drug Discovery. 2020;19:39–56.
22. Cao Y. Adipocyte and lipid metabolism in cancer drug resistance. J Clin Investig. 2019;129:3006–17.
23. Iwamoto H, Abe M, Yang Y, Cui D, Seki T, Nakamura M, Hosaka K, Lim S, Wu J, He X, et al. Cancer lipid metabolism confers antiangiogenic drug resistance. Cell Metabolism. 2018;28.
24. Yoshida GJ. Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res. 2015;34:111.
25. Liu R, Lee J-H, Li J, Yu R, Tan L, Xia Y, Zheng Y, Bani X-L, Lorenzi P, Chen Q, et al. Choline kinase alpha 2 acts as a protein kinase to promote lipolysis of lipid droplets. Mol Cell. 2021;81.
26. Liu R, Li J, Zhao J, Lee J-H, Qiu X, Xiao Y, Zhang B, Hao Y, Li M, Chen Q. Innate immune response orchestrates phospholipid phosphatase synthetases to support DNA repair. Cell Metab. 2021;33.
27. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell. 2012;21:297–308.
28. Kreuzaler P, Panina Y, Segal J, Yuneva M. Adapt and conquer: metabolic flexibility in cancer growth, invasion and evasion. Mol Metab. 2020;33.
29. Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol. 2011;27:441–64.
30. Luengo A, Li Z, Gui DY, Sullivan LB, Zagoroula M, Do BT, Ferreira R, Naamati A, Ali A, Lewis CA, et al. Increased demand for NAD relative to ATP drives aerobic glycolysis. Mol Cell. 2021;81.
31. Liu J, Zhang C, Hu W, Feng Z. Tumor suppressor p53 and metabolism. J Mol Cell Biol. 2019;11:284–92.
32. Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20:74–88.
33. Papagiannakopoulou T, Bauer MR, Davidson SM, Heimann M, Subbaraj L, Bhatkar A, Bartlebaugh J, Vander Heiden MG, Jacks T. Circadian rhythm disruption promotes lung tumorigenesis. Cell Metab. 2016;24:324–31.
34. Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell. 2017;66;789–800.
35. Lin S-C, Hardie DG. AMPK: sensing glucose as well as cellular energy status. Cell Metab. 2018;27;299–313.
36. Labuschagne CF, Zani F, Vourosen KH. Control of metabolism by p53: cancer and beyond. Biochim Biophys Acta. 2018;1870:32–42.
37. Gomes AS, Ramos H, Soares J, Saraiva L. p53 and glucose metabolism updates. Drug Resistance Updates. 2011;14:191–201.
38. Lin S-C, Hardie DG. AMPK: sensing glucose as well as cellular energy status. Cell Metab. 2018;27;299–313.
39. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17;351–362.
40. Zhang Y, Yu G, Chu H, Wang X, Xiong L, Cai G, Liu R, Gao H, Tao B, Liu W, et al. Macrophage-associated PGK1 phosphorylation promotes aerobic glycolysis and tumorigenesis. Mol Cell. 2018;71.
Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009;15:6479–83.

Li F, Wang Y, Zeller KJ, Pottier JJ, Wonsey DR, O’Donnell KA, Kim JW, Yustein JT, Lee LA, Dang CV. Myc stimulates nucleoli encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol. 2005;25:6225–34.

Yun CW, Han Y-S, Lee SH. PGC-1α Controls mitochondrial biogenesis in drug-resistant colorectal cancer cells by regulating endoplasmic reticulum stress. Int J Mol Sci. 2019;20:20.

Jiang J, Wang K, Chen Y, Huang C. Redox regulation in tumor cell epithelial-mesenchymal transition: molecular basis and therapeutic strategy. Signal Transduct Target Ther. 2017;2:17036.

Zhang G, Frederic DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest. 2016;126:1834–56.

Xu R, Luo X, Ye X, Li, Liu H, Du Q, Zhai Q, SIRT1/PGC-1α/Ppargc1a correlate with hypoxia-induced chemoresistance in non-small cell lung cancer. Front Oncol. 2021;11:682762.

Gopal NV, Rizos H, Chen G, Deng W, Frederic DT, Cooper ZA, Scoley RA, Pupo G, Khvorov K, Sehgal V, et al. Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC-1α and oxidative phosphorylation in melanoma. Can Res. 2014;74:7037–47.

McCann E, O’Sullivan J, Marcone S. Targeting cancer-cell mitochondria and metabolism to improve radiotherapy response. Translational oncology. 2021;14:100905.

Kondapalli C, Kazlauskaite A, Zhang N, Woodroof Hi, Campbell DG, Gourlay R, Burchell L, Walden H, Macartney TJ, Deak M, et al. PINK1 is activated by mitochondrial membrane potential depolarization and stimulates Parkin E3 ligase activity by phosphorylating Serine 65. Open Biol. 2012;2:120080.

O’Flanagan CH, Morais VA, Wurst W, De Strooper B, O’Neill C. The interaction between PINK1 and Parkin is required for maintaining mitophagy function. Autophagy. 2021;17:2223–37.

Wu H, Wang Y, Li W, Chen H, Du L, Liu D, Xu T, Liu L, Chen Q. Deficiency of mitophagy receptor FUNDC1 impairs mitochondrial quality and aggravates dietary-induced obesity and metabolic syndrome. Autophagy. 2019;15:1882–98.

Yan C, Gong L, Chen L, Xu M, Abou-Hasan D, Tang M, Desautels L, Song Z, PHB2 (prohibitin 2) promotes PINK1-Parkin/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis. Autophagy. 2020;16:419–34.

Murakawa T, Yamaguchi O, Hashimoto A, Hikosho S, Takeda T, Oka T, Yasui H, Ueda H, Akazawa Y, Nakayama H, et al. Bcl-2-like protein 13 is a mammalian Atg32 homologue that mediates mitophagy and mitochondrial fragmentation. Nat Commun. 2015;6:7527.

Guan Y, Wasserman Y, Li B, Shen K, Li Q, Ni Y, Huang L. Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics. Cancer Cell Int. 2021;21:350.

Hou H, Er P, Cheng J, Chen X, Ding X, Wang Y, Chen X, Yuan Z, Pang Q, Wang P, et al. High expression of FUNDC1 predicts poor prognostic outcomes and is a promising target to improve chemoradiotherapy effects in patients with cervical cancer. Cancer Med. 2017;6:1871–81.

Wu H, Wang T, Liu Y, Li X, Xu S, Wu C, Zou H, Cao M, Jin G, Lang J, et al. Mitophagy promotes sorafenib resistance through hypoxia-inducible ATAD3A-dependent Axis. J Exp Clin Cancer Res. 2020;39:274.

Yamashita K, Miyata H, Makino T, Masuike Y, Furukawa H, Tanaka K, Miyazaki Y, Takahashi T, Kurokawa Y, Yamazaki M, et al. High expression of the mitophagy-related protein PINK1 is associated with a poor response to chemotherapy and a poor prognosis for patients treated with neoadjuvant chemotherapy for esophageal squamous cell carcinoma. Ann Surg Oncol. 2017;24:4025–32.

Villa E, Proics E, Rubio-Patiño C, Obba S, Zunino B, Bossowski JP, Rozier RM, Chiche J, Mondragón L, Riley JS, et al. Parkin-independent mitophagy controls chemotherapeutic response in cancer cells. Cell Rep. 2017;20:1269–79.

Su Y-C, Davuluri GVN, Chen C-H, Shiau D-C, Chen C-C, Chen C-L, Lin Y-S, Chang C-P. Galectin-1-induced autophagy facilitates cisplatin resistance of hepatocellular carcinoma. PLoS ONE. 2016;11:e0148408.

Riccotola F, Izzo V, Nisco-Santano M, Vacchelli E, Galluzzi L, Maira MC, Kroemer G. Regulation of autophagy by stress-responsive transcription factors. Semin Cancer Biol. 2013;23:310–22.

Chen H, Vermut M, Wang YE, Chorny A, Prolla TA, McCaffrey JM, Chan DC. Mitochondrial fission is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations. Cell. 2010;141:280–9.

Patten DA, Wong J, Khacho M, Soubannier V, Mailloux RJ, Pilone-Larose K, MacLaurin JG, Park DS, McBride HM, Trinkle-Mulcahy L, et al. OPA1-dependent cristae modulation is essential for cellular adaptation to metabolic demand. EMBO J. 2014;33:2676–91.

Dias-Silva Rosa SC, Martins MD, Fierro JT, Nguyen L, Kereliuk SM, Hai Y, Chapman D, Diehl-Jones W, Allani M, West AR, et al. BNIP3L/Nix-induced mitochondrial fission, mitophagy, and impaired myocyte glucose uptake are abrogated by PRRK1/PKA phosphorylation. Autophagy. 2021;17:2257–72.

Liu H, Ho PW-L, Leung CT, Pang SY-Y, Chang EES, Choi ZY-K, Kung MH-W, Ramdien DB, Ho S-L. Aberrant mitochondrial morphology and function associated with impaired mitophagy and DNMT1-MAPK/ERK signaling are found in aged mutant Parkinsonian LRRK2 mice. Autophagy. 2021;17:3196–200.

Bao D, Zhao J, Zhou X, Yang Z, Chen Y, Zhu J, Yuan P, Yang J, Qin T, Wan S, et al. Mitochondrial fission-induced mtDNA stress promotes tumor-associated macrophage infiltration and HCC progression. Cancer Discov. 2019;9:580–90.

Osman C, Noriega TR, Okreglak V, Jung WC, Pinter P. Integrity of the yeast mitochondrial genome, but not its distribution and inheritance, is required on mitochondrial fission and fusion. Proc Natl Acad Sci USA. 2015;112:E947–56.

Yu Y, Peng X-D, Qian X-J, Zhang K-M, Huang X, Chen Y-H, Li Y-T, Feng G-K, Zhang H-L, Xu X-L, et al. Fis1 phosphorylation by Met promotes mitochondrial fission and hepatocellular carcinoma metastasis. Signal Transduct Target Ther. 2021;6:401.

Rambold AS, Kostelecky B, Elia N, Lippincott-Schwartz J. Tubular network formation protects mitochondria from autophagosomal degradation during nutrient starvation. Proc Natl Acad Sci USA. 2011;108:1910–9.

Hosseinzadeh A, Bahrampour Juybari K, Kamarul T, Sharif AM. Protective effects of atorvastatin on high glucose-induced oxidative stress and mitochondrial apoptotic signaling pathways in cultured chondrocytes. J Physiol Biochem. 2019;75:153–62.

Nanda N. Fine structure of the erythrocytic stages of Plasmodium vivax and the host cell alterations. Indian J Malariol. 1990;27:65–78.

Han X-J, Yang Z-J, Jiang L-P, Wei Y-F, Liao M-F, Qian L, Yu Y, Huang X, Wang J-B, Xin H-B, et al. Mitochondrial dynamics regulates hypoxia-induced migration and antineoplastic activity of cisplatin in breast cancer cells. Int J Oncol. 2015;46:691–700.

Chen X, Gytsou C, Zhou H, Narang S, Reyna DE, Lopez A, Sakkellaropoulos G, Gong Y, Kloetgen A, Yap YS, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment. Cancer Discov. 2019;9:890–909.

Song J, Zhao W, Lu C, Shao X. LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via activating the AMPK-Mfn2 signaling pathway. Cancer Cell Int. 2019;19:60.

Decker CW, Garcia J, Gatchalian K, Arceneaux D, Arceneaux D, Baez S, Carreño B, de la Torre G, Delgado S, et al. CerS6 regulates cisplatin resistance in cancer cells. Cell Death Dis. 2016;7:e2459.
transfer via tunneling nanotubes is an important mechanism by which mesenchymal stem cells enhance macrophage phagocytosis in the in vitro and in vivo models of ARDS. Stem Cells (Dayton, Ohio). 2016;34:2210–23.

168. Naonni MG, Carfino S, Canonicò B, Burattini S, Cesaroni E, Papa S, Paglierini M, Ambrogi M, Balduzzi W, Lucetti F. Melatonin reshapes the mitochondrial network and promotes intercellular mitochondrial transfer via tunneling nanotubes after ischemic-injury in hippocampal HT22 cells. J Pineal Res. 2021; e12747.

169. Griesinger E, Moschini R, Biondani G, Peyron J-F. Mitochondrial transfer in the leukemia microenvironment. Trends Cancer. 2017;3:828–39.

170. Shanmughapriya S, Langford D, Natarajaseenivasan K. Inter and Intra- mitochondrial trafficking in inflammation and disease. Ageing Res Rev. 2020;62:101128.

171. Tan AS, Baty JW, Dong LF, Beazwok-Geleata A, Endaya B, Goodvin J, Bajzikova M, Kovačević J, Petković D, Yuan B, et al. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial DNA. Cell Metab. 2015;21:81–94.

172. Pasquier J, Guerrouahen BS, Al-Thawadi H, Ghiabi P, Maleki M, Abu-Kaoud N, Jacob A, Mirshahi M, Galis R, Raﬁi S, et al. Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance. J Transl Med. 2013;11:94.

173. Spees JL, Olson SD, Whitney MJ. Mitochondrial transfer between cells can rescue aerobic respiration. Proc Natl Acad Sci U S A. 2006;103:1283–8.

174. Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, Saland E, Marlein CR, Zaitseva L, Piddock RE, Robinson SD, Edwards DR, Shafat M. Mitochondrial-derived peptides? Trends Endocrinol Metab. 2013;24:222–8.

175. Patheja P, Sahu K. Macrophage conditioned medium induced cellular network formation in MCF-7 cells through enhanced tunneling nanotube formation and tunneling nanotube mediated release of viable cytoplasmic fragments. Exp Cell Res. 2017;355:182–93.

176. Guaragnella N, Giannattasio S, Moro L. Mitochondrial dysfunction in cancer chemoresistance. Biochem Pharmacol. 2014;92:62–72.

177. Gustafsson CM, Falkenberg M, Larsson N-G. Maintenance and expression of mammalian mitochondrial DNA. Annu Rev Biochem. 2016;85:133–60.

178. Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, Thiru P, Reidy M, Kugener G, Rossen J, et al. Mitochondrial metabolism promotes adaptability and stress responses independently of respiratory chain deficiency in the heart. Cell Metab. 2014;19:450–9.

179. Bahat A, Perlberg S, Melamed-Book N, Isaac S, Eden A, Lauria I, Langer T, Orly J. Transcriptional activation of LON Gene by a new form of mitochondrial stress: a role for the nuclear respiratory factor 2 in STAR overload response (SOR). Mol Cell Endocrinol. 2015;408:62–72.

180. Tsvetkov P, Detappe A, Cai K, Keys HR, Brune Z, Ying W, Thiru P, Reidy M, Kugener G, Rossen J, et al. Mitochondrial metabolism promotes apoptosis in pancreatic cells. Mol Cell. 2019;15:681–9.

181. Shen L, Zhou L, Xia M, Lin N, Ma J, Dong D, Sun L. PGC-1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nuclear-mitochondrial transcriptional feedback. Exp Cell Res. 2021;398:112369.

182. Zhang J, Wang X, Vikash V, Ye Q, Wu D, Liu Y, Dong W. ROS and ROS-mediated cellular signaling. Oxid Med Cell Longev. 2016;2016:4350965.

183. Sankar N, del’ombe PP, Migney GA. Calcineurin-NFATc regulates type 2 inositol 1,4,5-trisphosphate receptor (InsP3R2) expression during cardiac remodeling. J Biol Chem. 2014;289:188–98.

184. Guangxin Zhou, Zhiqiang Zhang, Zhengguang Chang, Yuzhi Wang, Junfang Ren. Mitochondria and mitochondrial dysfunction in cancer stem cell multidrug resistance. Stem Cells Dev. 2019;28:2067–80.

185. Garcia-Mayea Y, Mir C, Marlon F, Pacucci R, ME LL. Insights into new mechanisms and models of cancer stem cell multidrug resistance. Semin Cancer Biol. 2020;60:166–80.
210. Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchison KE, Nixon MJ, Estrada MV, Sanchez V, Sanders ME, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 2017;26:633–47.

211. Kim B, Jung JW, Jung J, Han Y, Suh DH, Kim HS, Dhanasekaran DN, Song YS. PGC1-alpha induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells. Oncotarget. 2017;8:60299–311.

212. Farnie G, Sotoga F, Lisanti MP. High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant. Oncotarget. 2015;6:3072–86.

213. Cocevt A, Ragazzi E, Montopoli M. Mitochondrial Involvement in Cisplatin Resistance. International journal of molecular sciences. 2019;20.

214. Ma Y, Wang L, Jia R. The role of mitochondrial dynamics in human cancers. Am J Cancer Res. 2020;10:1278–93.

215. Wang Y, Liu H-H, Cao Y-T, Zhang L-L, Huang F, Yi C. The role of mitochondrial dynamics and mitophagy in carcinogenesis, metastasis and therapy. Front Cell Dev Biol. 2020;8:413.

216. Kingnate C, Charoenkwan K, Kumfu S, Chattipakorn N, Chattipakorn SC. Mitochondrial dynamics: a major target in stimulating drug sensitivity in human leukemia stem cells. Cancer Lett. 2020;475:66–76.

217. Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9:216–37.

218. Vaian K, Werner M, Chandel NS. Mitochondrial metabolism as a target for cancer therapy. Cell Metab. 2020;32:341–52.

219. Pesini A, Iglesias E, Garrido N, Bayona-Bafaluy MP, Montoya J, Ruiz-Pesini E. OXPHOS, pyrimidine nucleotides, and Alzheimer’s disease: a pharmacogenomics approach. J Alzheimer’s Dis. 2014;42:87–96.

220. Morgan JM, Duncan MC, Johnson KS, Diepold A, Lam H, Dupzyk AJ, Martin LR, Wong WR, Arthur JP, Lagaccia RG, et al. Piericidin A1 blocks Ysc Type III secretion system needle assembly. MSphere. 2017;2.

221. Panina SB, Pei J, Baran N, Konopleva M, Kirienko NV. Utilizing synergistic metabolic vulnerabilities of diffuse large B-cell lymphoma. EBioMedicine. 2018;34:256–66.

222. Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9:216–37.

223. Prochazka L, Koudelka S, Dong L-F, Stursa J, Goodwin J, Neca J, Jirikova K, et al. Disrupting mitochondrial Ca2+ homeostasis causes extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Can Res. 2019;79:1266–99.

224. Dong L-F, Jameson VJA, Tilly D, Prochazka L, Rohlena J, Valls K, Truska J, Zabolova R, Mahdavian E, Kluckova K, et al. Mitochondrial targeting of α-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy. Free Radical Biol Med. 2011;50:1456–55.

225. Dorrle J, Gerauer H, Wachtler Y, Zunino SJ, Reseland A, Forsanretor induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Can Res. 2019;79:1266–99.

226. Salata GC, Malagó ID, Carvalho Dartora VFM, Marçal Pessoa AF, Fantini MCDA, Costa SKR, Machado-Neto JA, Lopes LB. Microemulsion for prolonged release of fenretinide in the mammary tissue and prevention of breast cancer development. Mol Pharm. 2021;18:3401–17.

227. Sundberg TB, Ney GM, Subramanian C, Oppari AW, Glick GD. The immunomodulatory benzodiazepine Bz-423 inhibits B-cell proliferation by targeting c-myc protein for rapid and specific degradation. Cancer Res. 2006;66:1775–82.

228. Alam MM, Sohoni S, Kalainayakan SP, Garrossian M, Zhang L. Cyclopamine tartrate, an inhibitor of Hedgehog signaling, strongly interferes with mitochondrial function and suppresses aerobic respiration in lung cancer cells. BMC Cancer. 2016:16:150.

229. Sohoni S, Ghosh P, Wang T, Kalainayakan SP, Vidal C, Dey S, Konduri PC, Zhang L. Elevated heme synthesis and uptake underpin intensified oxidative metabolism and tumorigenic functions in non-small cell lung cancer cells. Can Res. 2019;79:2511–25.

230. Dekehr AS, Shah K, Ducker GS, Katinas JW, Wongs-Roush J, Nayeem MJ, Doshi A, Ning C, Bao X, Frühaufl J, et al. Novel pyrrole[3,2-i]pyrimidine compounds target mitochondrial and cytotoxic one-carbon metabolism with broad-spectrum antitumor efficacy. Mol Cancer Ther. 2019;18:1787–99.

231. Ducker GS, Chergurovich JM, Mainolfi N, Sun V, Jeong SK, Hsin-Jung Li S, Friedman A, Manfredi MG, Giti A, Kim H, et al. Human SHM1 inhibitors reveal defensive glycin import as a targetable metabolic vulnerability of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2017;114:11404–9.

232. Paiardini A, Fiascarielli A, Rinaldo S, Daidone F, Giardina G, Koes DR, Paronisi A, Montoni G, Marani M, Paone A, et al. Screening and in vitro testing of antifolate inhibitors of human cytosolic serine hydroyxymethyltransferase. ChemMedChem. 2015;10:490–7.

233. Jin R, Liu B, Liu X, Fan Y, Peng W, Huang C, Marcus A, Sica G, Gilbert-Ross M, Liu Y, et al. Leflunomide suppresses the growth of LB1-inactivated tumors in the immune-competent host and attenuates distant cancer metastasis. Mol Cancer Ther. 2021;20:274–83.

234. Rosenzweig M, Palmer J, Tsa I, Synold T, Wou T, Xuo S, Hammond SN, Buechter R, Duarte L, Hut M, et al. Repurposing leflunomide for relapsed/refractory multiple myeloma a phase I study. Leuk Lymphoma. 2020;61:1669–77.

235. Molina JR, Sun Y, Protopopova M, Gera S, Bandi M, Bristow C, Mccafos T, Morlachlic P, Ackroyd J, Agip-A, NA, et al. An inhibitor of oxidative phosphorylation exploits cancer vulnerability. Nat Med. 2018;24:1036–46.

236. Pardee TS, Anderson RG, Pidada KM, Isom S, Gheadaldui LP, Miller LD, Chou JW, Jin G, Zhang W, Ellis LR, et al. A phase I study of CPI-613 in combination with high-dose cytarine and mitoxantrone for relapsed or refractory acute myeloid leukemia. Clin Cancer Res. 2018;24:2060–73.

237. Galan-Cobo A, Sthitadeaithapbhoop P, Xu Q, Poteete A, Piesega MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, et al. LB1 and KEAP1/NRF2 pathways cooperatively promote metabolic reprogramming with enhanced glutamine dependence in -mutant lung adeno-carcinoma. Cancer Res. 2019;79:351–67.

238. Nishi K, Suzuki M, Yamasako M, Atogu Y, Yamasaki K, Otogai M, Yumita N. Glutamine deprivation enhances acetyl-CoA carboxylase inhibitor-induced death of human pancreatic cancer cells. Anticancer Res. 2018;38:6683–9.

239. Jain S, Hu C, Klusa L, Ke W, Tian G, Giurgiu M, Bleilevens A, Campos AR, Charnbono A, Diederik E, et al. Metabolic targeting of cancer by a ubiquitous incompetent inhibitor of mitochondrial complex I. Cell Chem Biol. 2021.

240. Liu Y, Zhang X, Zhou M, Nan X, Chen X, Zhang X. Mitochondrial-targeting lindamidine-doxorubicin nanoparticles for synergistic chemotherergy to conquer drug resistance. ACS Appl Mater Interfaces. 2017;9:43496–507.

241. Abraham I, Wolf CL, Sampson KE. Non-glucocorticoid steroid analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine. Cancer Chemother Pharmacol. 1993;32:116–22.

242. Ohshima Y, Takata N, Suzuki-Karasaki M, Yoshida Y, Tokuhashi Y, Suzuki-Karasaki Y. Disrupting mitochondrial Ca2+ homeostasis causes extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Can Res. 2013;78:4671–9.

243. Dong L-F, Jameson VJA, Tilly D, Prochazka L, Rohlena J, Valls K, Truska J, Zabolova R, Mahdavian E, Kluckova K, et al. Mitochondrial targeting of α-tocopheryl succinate enhances its pro-apoptotic efficacy: a new paradigm for effective cancer therapy. Free Radical Biol Med. 2011;50:1456–55.

244. Abraham I, Wolf CL, Sampson KE. Non-glucocorticoid steroid analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine. Cancer Chemother Pharmacol. 1993;32:116–22.

245. Otagiri M, Yumita N. Glutamine deprivation enhances acetyl-CoA carboxylase inhibitor-induced death of human pancreatic cancer cells. Anticancer Res. 2018;38:6683–9.
249. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Can Res. 2007;67:3646–70.

250. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417.

251. Lemarie A, Grimm S. Mitochondrial respiratory chain complexes: apoptosis sensors mutated in cancer? Oncogene. 2011;30:3985–4003.

252. Pang Y, Lu Y, Caisova V, Lu Y, Bullova P, Huynh T-T, Zhou Y, Yu D, Fryzak S, Hartmann I, et al. Targeting NAD/PARP DNA repair pathway as a novel therapeutic approach to Mutated cluster I phaeochromocytoma and paraganglioma. Clin Cancer Res. 2018;24:3432–32.

253. Fong W, To KKW. Drug repurposing to overcome resistance to various therapies for colorectal cancer. Cell Mol Life Sci. 2019;76:3383–406.

254. Marinello PC, Panis C, Silva TNX, Binato R, Abdelhay E, Rodrigues JA, Mencalha AL, Lopes NMD, Luiz RC, Cecchini R, et al. Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes. Sci Rep. 2019;9:5864.

255. Lee JO, Kang MJ, Byun WS, Kim SA, Seo IH, Han JA, Moon JW, Kim JH, Kim SJ, Lee EJ, et al. Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAS1. Breast Cancer Res. 2019;21:115.

256. Mynhardt C, Damelin LH, Jivan R, Peres J, Prince S, Veale RB, Arrieta O, Barrón F, Padilla M-ÁS, Avilés-Salas A, Ramírez-Tirado LA, Liang D, Wang A-T, Yang Z-Z, Liu Y-J, Qi X-R. Enhance cancer cell metabolism caused by combination of 2-deoxy-D-glucose and cisplatin. Exp Ther Med. 2018;67:3364–70.

257. Chakraborty PK, Mustafi SB, Ganguly S, Chatterjee M, Raha S. Resveratrol from grapes, induces apoptosis via a novel mitochondrial pathway. New Bio. 2015;22:883–900.

258. Han YH, Park WH. Growth inhibition in antimycin A treated-lung cancer H9c2 cells. Food Funct. 2015;6:549–57.

259. Tinhofer I, Bernhard D, Senfter M, Another G, Loefflmer M, Kroemer G, Koff R, Cordsan A, Greil R, Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J. 2001;15:1613–5.

260. Shi Y, Lim SK, Liang Q, Iyer SV, Wang H-Y, Wang Z, Xie X, Sun D, Chen Y-J, Tabar V, et al. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Nature. 2019;567:341–6.

261. You K-R, Wen J, Lee S-T, Kim D-G. Cytochrome c oxidase subunit III: a novel therapeutic target in hepatocellular carcinoma. Biochem Pharmacol. 2018;119:1193–203.

262. Livingstone E, Swann S, Lilla C, Schadendorf D, Roesch A. Combining BRAF(V600E) inhibitor with modulators of the mitochondrial bioenergy metabolism to overcome drug resistance in metastatic melanoma. Exp Dermatol. 2015;24:709–10.

263. Beloueche-Babani M, Wantuch S, Casals Galobart T, Konioroudou M, Parkes HG, Arunav Y, Chung Y-L, Eykyn TR, Smith PD, Leach MO. MCT1 inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Can Res. 2017;77:5913–24.

264. Kameritsch P, Singer M, Nuernbergk C, Rios N, Reyes AM, Schmidt FA, Golombieski RM, da Silva Loreto EL, da Rocha JBT, Fighiera MR, Soares FA. Neuroprotective effect of diphenyl diselenide in a experimental stroke model: maintenance of redox system in mitochondria of brain regions. Neurotox Res. 2014;26:317–30.

265. Han SJ, Choi HS, Kim JI, Park KM. Isoctrate dehydrogenase 2 deficiency aggravates prolonged high-fat diet intake-induced hyper-tension. Redox Biol. 2020;34:101548.

266. Mavri-Damelin D. Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in cecal squamous cell carcinoma. J Cell Biochem. 2018;119:1193–203.

267. Peng L, Jiang J, Prokopova K, Dong L, Neuzil J. Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner. BMC Cancer. 2015;15:401.

268. Wang A-T, Yang Z-Z, Liu Y-J, Tabar V, et al. Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma. Nature. 2019;567:341–6.

269. Chu M, Zheng C, Chen C, Song G, Hu X, Wang Z-W. Targeting cancer stem cells by nutraceuticals for cancer therapy. Seminars Cancer Biol. 2021;119:1193–203.

270. Chakraborty PK, Mustafi SB, Ganguly S, Chatterjee M, Raha S. Resveratrol as an anti-cancer agent: a review. Crit Rev Food Sci Nutr. 2018;58:1428–47.

271. You K-R, Wen J, Lee S-T, Kim D-G. Cytochrome c oxidase subunit III: a molecular marker for N-(4-hydroxyproline)retinamine-induced oxidative stress in hepatoma cells. J Biol Chem. 2002;277:3870–7.

272. Villani MG, Appierto V, Cavadinine A, Bettiga A, Pirreti A, Claget-Dame M, Curley RW, Formelli F. 4-Oxo-fenretinide, a recently identified fenreti-nide metabolite, induces marked G2-M cell cycle arrest and apoptosis in ferretine-sensitive and ferretine-resistant cell lines. Can Res. 2006;66:3238–47.

273. Fazi B, Bursch W, Firnia GM, Nardacci R, Piccinanti M, Di Sano F, Prieda L. Feretininduces autophagic cell death in caspase-defective breast cancer cells. Autophagy. 2008;4:435–41.

274. Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP. Mechanism of synergy of N-(4-hydroxyproline)retinamine and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst. 2008;100:580–95.

275. Kameritsch P, Singer M, Nuernbergk C, Rios N, Reyes AM, Schmidt FA, Golombieski RM, da Silva Loreto EL, da Rocha JBT, Fighiera MR, Soares FA. Neuroprotective effect of diphenyl diselenide in a experimental stroke model: maintenance of redox system in mitochondria of brain regions. Neurotox Res. 2014;26:317–30.

276. Chalker J, Gardiner D, Kuksal N, Mailloux RJ. Characterization of the impact of glutaredoxin-2 (GRX2) deficiency on superoxide/hydrogen peroxide release from cardiac and liver mitochondria. Redox Biol. 2018;15:216–27.

277. Kameritsch P, Singer M, Nuernbergk C, Rios N, Reyes AM, Schmidt K, Kisch J, Schneider H, Müller S, Pogoda K, et al. The mitochondrial thio-redoxin reductase system (TrxR2) in vascular endothelium controls peroxy-nitrite and tissue integrity. Proc Natl Acad Sci USA. 2011;118:236–48.

278. Sullivan LB, Martinez-Garcia E, Nguyen H, Muller AR, Dufour E, Sudarshan S, Licht JD, Deberardinis RJ, Chandel NS. The proto-oncometab-o-lite fumarate binds glutathione to amplify ROS-dependent signalling. Mol Cell. 2013;51:236–48.

279. Okon IS, Zou M-H. Mitochondrial ROS and cancer drug resistance: implications for therapy. Pharmacol Res. 2015;100:170–40.

280. Dekhne AS, Ning C, Nayeen MJ, Shah K, Kalpage H, Frühauf J, Wallace- Shan S, Licht JD, Deberardinis RJ, Chandel NS. The proto-oncometab-o-lite fumarate binds glutathione to amplify ROS-dependent signalling. Mol Cell. 2013;51:236–48.
realigning cellular oxidative status in colorectal cancer. Cell Rep. 2021;57:110069.

287. Minton DR, Nam M, McLaughlin DJ, Shin J, Bayraktar EC, Alvarez SW, Sviderskiy VO, Papagiannakopoulos T, Sabatini DM, Bisoyi K, et al. Serine catabolism by SHMT2 is required for proper mitochondrial translation initiation and maintenance of formylmethionyl-tRNAs. Mol Cell. 2018;69.

288. Stuart SD, Schaulbe A, Gupta S, Kennedy AD, Keppler BR, Bingham Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Cenigaonandia-Campillo A, Serna-Blasco R, Gómez-Ocabo L, Solanes-Hui S, Ghergurovich JM, Morscher RJ, Jang C, Teng X, Lu W, Esparza Romero R, Sayana P, Jankovic J. Animal models of Parkinson's disease: a gateway to therapeutic neurotherapeutics. 2014;23:517–28.

289. Hui S, Ghergurovich JM, Morscher RJ, Jang C, Teng X, Lu W, Esparza Romero R, Sayana P, Jankovic J. Animal models of Parkinson's disease: a gateway to therapeutic neurotherapeutics. 2014;23:517–28.

290. Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, et al. Keap1 loss overexpression drives renal cell carcinoma in a mouse model through glutaminase C: a direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activation loop of mitochondrial glutaminase C. Mol Cancer Ther. 2011;10:3995–406.

291. Altman BJ, Stone ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16:619–34.

292. Hui S, García-Foncillas J, Aguilera Ó. Vitamin C activates pyruvate dehydrogenase to cancer therapy. Nat Rev Cancer. 2016;16:619–34.

293. Brown TP, Rumsby PC, Capleton AC, Rushion L, Leyt LS. Pesticides and Parkinson's disease—is there a link? Environ Health Perspect. 2006;114:156–64.

294. Zhao B, Shi Z. Copper-catalyzed intermolecular heck-like coupling of cyclobutanone oximes initiated by selective C–C bond cleavage. Angew Chem Int Ed Engl. 2015;54:12653–4.

295. Xiang Y, Stine ZE, Xu J, Liu Y, O'Connor RS, Altman BJ, Hseih AL, Gouw AM, Thomas ACi, Gao P, et al. Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. J Clin Investig. 2015;125:2923–306.

296. Rajeshkumar NV, Yabuuchi S, Pai SG, De Oliveira E, Kamphorst JJ, Rabinowitz JD, Tejero H, Al-Shahrour F, Hidalgo M, Maitra A, et al. Treatment of pancreatic cancer patient-derived xenograft panel with metabolite inhibitors reveals efficacy of phenformin. Clin Cancer Res. 2017;23:1362–8.

297. Setzler MJ, Bennett BD, Joshi AD, Gouw P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Shusser BJ, Rabinowitz JD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Can Res. 2010;70:8981–7.

298. Stalnacker CA, Erickson JW, Cerione RA. Conformational changes in the activation loop of mitochondrial glutaminase C: a direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators. J Biol Chem. 2017;292:6095–107.

299. Chakrabarti G, Moore ZR, Luo X, Ilcheva M, Ali A, Padanad M, Zhou Y, Xie Chen X, Zhang X, Kubo H, Harris DM, Mills GD, Moyer J, Berretta R, Potts IDH1. Can Res. 2010;70:8981–7.

300. Bravo R, Vicencio JM, Parra V, Troncoso R, Munoz JP, Bui M, Quiroga C, Rodriguez AE, Verdejo HE, Ferreria J, et al. Increased ER-mitochondrial coupling promotes mitochondrial respiration and bioenergetics during early phases of ER stress. J Cell Sci. 2011;124:2143–52.

301. O-Uchi J, Jhun BS, Hurst S, Bissett S, Gross P, Chen M, Kettlewell S, Park J, Oyamada H, Smith GL, et al. Overexpression of tyrosine receptor type 1 enhances mitochondrial fragmentation and Ca2⁺-induced ATP production in cardiac H9c2 myoblasts. Am J Physiol Heart Circulatory Physiol. 2013;305:H1736–H51.

302. Chen X, Zhang X, Kubo H, Harris DM, Mills GD, Moyer J, Berretta R, Potts ST, Marshall JD, Houser SR. Ca2⁺ influx-induced sarcoplasmic reticulum Ca2⁺ overload causes mitochondrial-dependent apoptosis in ventricular myocytes. Circ Res. 2005;97:1009–17.

303. Takada N, Ohshima Y, Suzuki-Karasaki M, Yoshida Y, Tokuhashi Y, Suzuki-Karasaki Y. Mitochondrial Ca2⁺ removal amplifies TRAIL cytotoxicity toward apoptosis-resistant tumor cells via promotion of multiple cell death modalities. Int J Onco. 2017;51:193–203.

304. Del Bufalo D, Biocci D, Soddu S, Laudonio N, D'Angelo C, Lascahi A, Zup G. Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. Clin Invest. 1996;98:1165–73.

305. Xu L, Xie Q, OI, Li, Wang C, Xu N, Liu W, Yu L, Xu Y, Bcl-2 overexpression reduces cisplatin cytotoxicity by decreasing ER-mitochondrial Ca2⁺ signaling in SKOV3 cells. Oncol Rep. 2018;39:985–92.

306. Eakins J, Bauch C, Woodhouse H, Park B, Bevan S, Dillworth C, Walker P. A combined in vitro approach to improve the prediction of mitochondrial toxicants. Toxicol Vitro. 2016;34:161–70.

307. Dowling RJO, Nairula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48:R31–43.

308. Eakins J, Bauch C, Woodhouse H, Park B, Bevan S, Dillworth C, Walker P. A combined in vitro approach to improve the prediction of mitochondrial toxicants. Toxicol Vitro. 2016;34:161–70.

309. Eakins J, Bauch C, Woodhouse H, Park B, Bevan S, Dillworth C, Walker P. A combined in vitro approach to improve the prediction of mitochondrial toxicants. Toxicol Vitro. 2016;34:161–70.

310. Eakins J, Bauch C, Woodhouse H, Park B, Bevan S, Dillworth C, Walker P. A combined in vitro approach to improve the prediction of mitochondrial toxicants. Toxicol Vitro. 2016;34:161–70.
structure-based virtual screening approach: challenges and break-throughs. Semin Cancer Biol. 2021;68:249–57.

329. Guo WF, Zhang S-W, Feng Y-H, Liang J, Zeng T, Chen L. Network controllability-based algorithm to target personalized driver genes for discovering combinatory drugs of individual patients. Nucleic Acids Res. 2021;49:e37.

330. Issa NT, Stathias V, Schuerer S, Dakshanamurthy S. Machine and deep learning approaches for cancer drug repurposing. Semin Cancer Biol. 2021;68:132–42.

331. Mottini C, Napolitano F, Li Z, Gao X, Cardone L. Computer-aided drug repurposing for cancer therapy: approaches and opportunities to challenge anticancer targets. Semin Cancer Biol. 2021;68:59–74.

332. Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60:1639–47.

333. Chen K, Qian W, Jiang Z, Cheng L, Li J, Sun L, Zhou C, Gao L, Lei M, Yan B, et al. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Mol Cancer. 2017;16:131.

334. Kang J, Jeong S-M, Shin DW, Cho M, Cho JH, Kim J. The associations of aspirin, statins, and metformin with lung cancer risk and related mortality: a time-dependent analysis of population-based nationally representative data. J Thoracic Oncol. 2021;16:78–86.

335. Emami Riedmaier A, Fisel P, Nies AT, Schaeffeler E, Schwab M. Metformin and cancer from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci. 2013;34:126–35.

336. Wang C, Jeong K, Jiang H, Guo W, Gu C, Lu Y, Liang J. YAP/TAZ regulates the effects of metformin in hepatocellular carcinoma. Clinical Cancer Res. 2013;19:5372–80.

337. Li L, Wang T, Hu M, Zhang Y, Chen H, Xu L. Metformin overcomes acquired resistance to EGFR TKIs in EGFR-mutant lung cancer via AMPK/ERK1/2 signaling pathway. Front Oncol. 2020;10:1605.

338. Chai X, Chai H, Yang X, Meng Y, Shi P, Gou S. Metformin increases sensitivity of pancreatic cancer cells to gemcitabine by reducing CD133+ cell populations and suppressing ERK/P70S6K signaling. Sci Rep. 2015;5:14404.

339. Melnik S, Dvornikov D, Müller-Decker K, Depner S, Stannek P, Meister M, Zou J, Li C, Jiang S, Luo L, Yan X, Huang D, Luo Z. AMPK inhibits Smad3-mediated autophagy and therapeutic effects of metformin in hepatocellular carcinoma. Clinical Cancer Res. 2013;19:5372–80.

340. Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, Houde VP, Muti P, Tsakiridis I, Steinberg GR. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Cancer Ther. 2020;19:1073.

341. Villani LA, Smith BK, Marcinko K, Ford RJ, Broadfield LA, Green AE, Houde VP, Muti P, Tsakiridis I, Steinberg GR. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol Cancer Ther. 2020;19:1073.

342. Miskimins WK, Ahn HJ, Kim JY, Ryu S, Jung YS, Choi JY. Synergistic anticancer effect of metformin and oxamate. PLoS ONE. 2014;9:e88576.

343. Zhang Y, Cheng J, Li J, He J, Li J, Xu F. The GPR-1 agonist exendin-4 attenuates hyperglycemia-induced chemoresistance in human endometrial cancer cells through ROS-mediated mitochondrial pathway. Front Oncol. 2021;11:7. 799330.

344. Groenendijk FH, Mellema WW, van der Burg E, Schut E, Hauptmann M, Horlings HM, Willems SM, van den Heuvel MM, Jonkers J, Smit EF, et al. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation. Int J Cancer. 2015;34:1364–44.

345. Lam TG, Jeong YS, Kim S-A, Ahn S-G. New metformin derivative HL156A prevents oral cancer progression by inhibiting the insulin-like growth factor/AKT/mammalian target of rapamycin pathway. Cancer Sci. 2018;109:699–709.

346. D'Amato MG, Marni S, Di Pastena F, Coni S, Mancino A, Cairoli S, Sambucini M, Infante P, Monteleone M, Petroni M, et al. Phenformin inhibits hedgehog-dependent tumor growth through a complex-I-independent redox/corepressor module. Cell. 2020;30:20.

347. de Mey S, Jiang H, Corbet W, Wang H, Dufail J, Law K, Bastien E, Verovski V, Gaevert T, Feron O, et al. Antidiabetic biguanides radiosensitize hypoxic colorectal cancer cells through a decrease in oxygen consumption. Front Pharmacol. 2018;9:1073.

348. Melnik S, Dvornikov D, Müller-Decker K, Depner S, Stannek P, Meister M, Zou J, Li C, Jiang S, Luo L, Yan X, Huang D, Luo Z. AMPK inhibits Smad3-mediated autophagy and therapeutic effects of metformin in hepatocellular carcinoma. Clinical Cancer Res. 2013;19:5372–80.

349. Li L, Wang T, Hu M, Zhang Y, Chen H, Xu L. Metformin overcomes acquired resistance to EGFR TKIs in EGFR-mutant lung cancer via AMPK/ERK1/2 signaling pathway. Front Oncol. 2020;10:1605.

350. Chai X, Chai H, Yang X, Meng Y, Shi P, Gou S. Metformin increases sensitivity of pancreatic cancer cells to gemcitabine by reducing CD133+ cell populations and suppressing ERK/P70S6K signaling. Sci Rep. 2015;5:14404.

351. Melnik S, Dvornikov D, Müller-Decker K, Depner S, Stannek P, Meister M, Warth A, Thomas M, Muley T, Risch A, et al. Cancer cell-specific inhibition of Wnt/B-catenin signaling by forcing intracellular acriflavine. Cell Discovery. 2018;4:37.

352. Rossini M, Martini F, Torreggiani E, Fortini F, Aquila G, Sega FVD, Paternani S, Pinton P, Maniscalco P, Cavalcioso G, et al. Metformin induces apoptosis and inhibits Notch1 in malignant pleural mesothelioma cells. Front Cell Dev Biol. 2020;8:534499.

353. Xiao H, Zhang J, Xu Z, Feng Y, Zhang M, Liu J, Chen R, Shen J, Wu J, Lu Z, et al. Metformin is a novel suppressor for transforming growth factor (TGF)-β1. Sci Rep. 2016;6:28597.

354. Zou J, Li C, Jiang S, Luo L, Yan X, Huang D, Luo Z. AMPK inhibits Smad3-mediated autoduction of TGF-β1 in gastric cancer cells. J Cell Mol Med. 2021;25:2806–15.

355. Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, Glasauer A, Rufou E, Mutlu GM, Budigner GS, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. eLife. 2014;3:e02242.

356. Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB. A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: therapeutic targeting of tumor mitochondria with lipophilic cationic compounds. Redox Biol. 2018;14:316–27.

357. Madrurai AK, Eron DM, Rahimi Y, Zhang X-M, Braddock DT, Albright RA, Pirogar BJ, Wood JL, Bhanot S, MacDonald MJ, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510:542–6.
367. Liu Y, Fang S, Sun Q, Liu B. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun. 2016;480:415–21.

368. Lin L, Lu W, Dai T, Chen H, Wang T, Yang L, Yang X, Liu Y, Sun D. Novel artemisinin derivatives with potent anticancer activities and the anti-coagulocytic cancer effect by the mitochondria-mediated pathway. Bioorg Chem. 2021;106:104496.

369. Tsui K-H, Wu M-Y, Lin L-T, Wen Z-H, Li Y-H, Chu P-Y, Li C-J. Disruption of mitochondrial homeostasis with artemisinin unearths anti-angiogenesis effects via autopharminemechanisms. Theranostics. 2019;9:6631–45.

370. Zhang J, Sun X, Wang L, Wong YK, Lee YM, Zhou C, Wu G, Zhao T, Yang L, Lu L, et al. Artearsunate-induced mitophagy alters cellular redox status. Redox Biol. 2018;19:263–73.

371. Ashton TM, Fokas E, Kunz-Schughart LA, Folkes LK, Anbalagan S, Kobayashi Y, Banno K, Kunitomi H, Tominaga E, Aoki D. Current state and outlook for drug repositioning anticipated in the field of ovarian cancer. J Gynecol Oncol. 2019;30:e10.

372. Weir SJ, Patton L, Castle K, Rajevski L, Lasper J, Schimmer AD. The repositioning of the anti-fungal agent ciclosporine as a novel therapeutic agent for the treatment of haematological malignancy. J Clin Pharmacol. 2011;51:138–48.

373. Tsunamoto H, Ueda T, Inoue K, Sakata K, Shibaara H, Sonoda T. Repurposing iraconazole as an anticancer agent. Oncol Lett. 2017;14:1240–6.

374. Chen K, Cheng L, Qian W, Jiang Z, Sun L, Zhao Y, Zhou Y, Zhao L, Wang P, Duan W, et al. Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-β/SMAD2/3 signaling. Oncol Rep. 2018;39:1573–82.

375. Pounds R, Leonard S, Dawson C, Keohan S. Repurposing iraconazole for the treatment of cancer. Oncol Lett. 2017;14:2587–92.

376. Deng H, Huang L, Liao Z, Liu M, Li Q, Xu R. Itraconazole inhibits the Hedgehog signaling pathway thereby inducing apoptosis-mediated accumulation of colon cancer cells. Cell Death Dis. 2020;11:539.

377. Liu R, Li J, Zhang T, Lou L, Chen Y, Wang K, Lei Y, yuan K, Li Y, Lan J, et al. Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking. Autophagy. 2014;10:1241–55.

378. Head SA, Shi W, Zhao L, Gorshkov K, Pasunooti KK, Liu JO. Simultaneous targeting of NPC1 and VDAC1 by itraconazole increased the intratumor drug levels and antitumor activity in a murine model of prostate cancer, but promotes the apoptosis of U251 and U87 cells via the PI3K/AKT/mTOR signaling pathway. Nutr Cancer. 2017;69:12083.

379. Zou X, Huang H, et al. Artesunate-induced mitophagy alters cellular redox status. Redox Biol. 2018;19:263–73.

380. Chen J, Sun X, Wang L, Wong YK, Lee YM, Zhou C, Wu G, Zhao T, Yang L, Lu L, et al. Artesunate-induced mitophagy alters cellular redox status. Redox Biol. 2019;19:263–73.

381. Rossi M, Rotblat B, Ansell K, Amelio I, Caraglia M, Bernazzoli B, Cavasotto CN, Ciechanover A, et al. High throughput screening for inhibitors of the HECT ubiquitin E3 ligase ITCH identifies antioxidants as regulators of apoptosis. J Biol Chem. 2010;285:3915–24.

382. Bai H, Huang Y, et al. Prazosin but not tamsulosin sensitises PC-3 and LNCaP prostate cancer cells to docetaxel. Pharmacology. 2018;102:1–10.

383. Zhang J, Fan J. Prazosin inhibits angiogenesis by downregulating expression of the angiogenic factor vascular endothelial growth factor/akt signaling pathway in a rat model of myocardial ischemia. Mol Med. 2019;25:1142–51.

384. Lee AB, Seo MJ, Kim J, Lee DM, Kim HY, Yoon MJ, Hoon H, Choi KS. Leucine-rich repeat protein 14-mediated Twist1 degradation. OncoTargets Ther. 2019;12:2415–26.

385. Barros-Reis M, Carvalho J, Mathonnet C, Moura I, Vilela P, Cordeiro J, et al. Imidazole antifungals induce autophagy and synergistic antitumor effects via the PI3K/AKT/mTOR pathway. Oncogenesis. 2019;8:301.

386. Jin et al. Journal of Hematology & Oncology. (2022) 15:97 Page 36 of 42
406. Lei B, Xu L, Zhang X, Peng W, Tang Q, Feng C. The proliferation effects of fluoxetin and amitriptyline on human breast cancer cells and the underlying molecular mechanisms. Environ Toxicol Pharmacol. 2021;83:103586.

407. Bielecka-Wajdman AM, Ludyga T, Machnik G, Golyszny M, Obuchowicz E. Tricyclic antidepressants modulate stressed mitochondria in globblasto
tumour-like cells. Cancer control. 2018;25:1007247818798594.

408. Bielecka-Wajdman AM, Lesiak M, Ludyga T, Sieroń A, Obuchowicz E. Reversing glioma malignancy: a new look at the role of antidepressant
drugs as adjuvant therapy for glioblastoma multiplex. Cancer Chem-
other Pharmacol. 2017;79:1249–56.

409. Daley E, Willkie D, Loesch A, Hargeaves IP, Kendall DA, Pilkington GT, Bates TE. Chlorpromazine: a novel anticancer agent with a mitochon-
drial target. Biochem Biophys Res Commun. 2005;328:623–32.

410. Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance efflux pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse models. Can Res. 2004;64:7562–9.

411. Lee CS, Kim YJ, Jang ER, Kim W, Myung SC. Fluoxetine induces apoptosis of ovarian carcinoma cell line OVCA-3 through reactive oxygen species-dependent activation of nuclear factor-kappaB. Basic Clin Pharmacol Toxicol. 2010;106:446–53.

412. Charles E, Hammad M, Kischel P, Delcoix V, Demeaux N, Castelbouc V, Vacher A-D, de Cauzac A, Ducet T, Nunes P et al. The antidepressant fluox-
etine induces necrosis by energy depletion and mitochondrial calcium overload. Oncotarget. 2017;8:3181–96.

413. Yuan S-Y, Cheng C-L, Ho H-C, Wang S-S, Chiu K-Y, Su C-K, Ou Y-C, Lin C-C. Nortriptyline induces mitochondria and death receptor-mediated apoptosis in bladder cancer cells and inhibits bladder tumor growth in vivo. Eur J Pharmacol. 2015;761:509–20.

414. Kayarhodi S, Fujimura Y, Fang J, Morsalin S, Rao VN, Reddy ESP. Anti-
epileptic drug targets evening sarcoma. J Pharm Pharmacol. 2014;1.

415. Tran LNK, Kichenadasse G, Morel KL, Lavranos TC, Klebe S, Lower KM, Tesei A, Brigliadori G, Carloni S, Fabbri F, Ulivi P, Arienti C, Sparatore A, Abaza M-SI, Bahman A-M, Al-Attiyah RaJ. Valproic acid, an anti-epileptic drug with histone deacetylase inhibitory activity, potentiates the cyto-
otoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia (New York, NY). 2019;11:597–608.

416. Upadhyay A, Amanullah A, Chhangani D, Joshi V, Mishra R, Mishra A. Nonsteroidal anti-inflammatory drugs. Clin Med Res. 2007;5:19–34.

417. de Groot DJA, de Vries EGE, Groen HJM, de Jong S. Non-steroidal anti-
flammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol. 2007;61:52–69.

418. Vaish V, Pipiani H, Rana C, Vaiphei K, Sanyal SN. NSAIDs may regulate mitochondrial dysfunction. Mol Neurobiol. 2016;53:6968–81.

419. Nakaya H, Li H, Liu J. NSAIDs use and reduced metastasis in cancer patients: results from a meta-analysis. Sci Rep. 2017;7:1875.

420. Wakabayashi K. NSAIDs as Cancer preventive agents. Asian Pacific J Cancer Prevent. 2000;1.

421. de Groot DJA, de Vries EGE, Groen HJM, de Jong S. Non-steroidal anti-
flammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol. 2007;61:52–69.

422. Gamberi T, Chiappetta G, Fiaschi T, Modesti A, Sorbi F, Magherini F. SMAC mimetics sensitize nonsteroi-
dal anti-inflammatory drug-induced apoptosis by promoting caspase-
3-mediated cytochrome c release. Can Res. 2008;68:276–84.

423. Gaziano JM, Brotton C, Coppolecchia R, Ciricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Hyatt TH, Bell PM, Klujike LA et al. Use of aspirin to reduce initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-
controlled trial. Lancet (London, England). 2018;392:1036–46.

424. Amarencio R, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P et al. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. Lancet Neurol. 2017;16:301–10.

425. Zhang X, Selvaraju K, Saei AA, D’Arcy P, Zubarev RA, Arnér ES, Linder S. Auranofin induces apoptosis by energy depletion and mitochondrial calcium overload. Oncotarget. 2015;6:36505–21.
467. Qu Y, Wang J, Sim M-S, Liu B, Giuliano A, Barsoum J, Cui X. Elesclomol, counteracted by Akt survival signaling, enhances the apoptotic effect of chemotherapy drugs in breast cancer cells. Breast Cancer Res Treat. 2010;121:311–21.

468. Hasinoff BB, Wu X, Yadav AA, Patel D, Zhang H, Wang D-S, Chen Z-S, Yalowich JC. Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II). Biochem Pharmacol. 2015;93:266–76.

469. Hasinoff BB, Yadav AA, Patel D, Wu X. The cytotoxicity of the anticancer drug elesclomol is due to oxidative stress indirectly mediated through its complex with Cu(II). J Inorg Biochem. 2014;137:22–30.

470. Nogai M, Vo NH, Shin Ogawa L, Chiminamada D, Inoue T, Chu J, Beaudette-Zlatanova BC, Liu R, Blackman RK, Barsoum J, et al. The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells. Free Radical Biol Med. 2012;52:2142–50.

471. Modica-Napolitano JS, Bharath UP, Hanlon AJ, Hurley LD. The anticancer agent elesclomol has direct effects on mitochondrial bioenergetic function in isolated mammalian mitochondria. Biomolecules. 2019;9.

472. Galiana-Roselló C, Aceves-Luquero C, González J, Martínez-Camarena Á, Villalonga R, Fernández de Mattos S, Soriano C, Llinares J, García-Españo E, Villalonga P, et al. Toward a rational design of polyamine-based zinc-chelating agents for cancer therapies. J Med Chem. 2020;63:1999–215.

473. Pan X, Li R, Guo H, Zhang W, Xu X, Chen X, Ding L. Dihydropyrimidine calcium channel blockers suppress the transcription of PD-L1 by inhibiting the activation of STAT3. Front Pharmacol. 2020;11:3926.

474. Hinz B, Ramer R. Anti-tumour actions of cannabinoids. Br J Pharmacol. 2019;176:1384–94.

475. Mahoney JM, Harris RA. Effect of 9-tetrahydrocannabinol on mitochondrial processes. Biochem Pharmacol. 1972;21:1217–26.

476. Whyte DA, Al-Hammadi S, Balhaj G, Brown OM, Penefsky HS, Soud A-K. Cannabinoids inhibit cellular respiration of human oral cancer cells. Pharmacology. 2010;85:328–35.

477. Rimmerman N, Ben-Hail D, Portz R, Juknat A, Kozea E, Daniels MP, Connelly PS, Leishman E, Bradshaw HB, Shoshan-Barmatz V, et al. Direct modulation of the outer mitochondrial membrane channel, voltage-dependent anion channel 1 (VDAC1) by cannabidiol: a novel mechanism for cannabinoid-induced cell death. Cell Death Dis. 2013;4:e949.

478. Trumbeckaite S, Cesna V, Juskaiteviene A, Baniene R, Gulbinas A. Different mitochondrial response to cisplatin and hyperthermia treatment in human AGS, Caco-2 and T3M4 cancer cell lines. J Bioenerg Biomembr. 2018;50:329–38.

479. Aryal B, Rao VA. Deficiency in cardiolipin reduces doxorubicin-induced oxidative stress and mitochondrial damage in human B-lymphocytes. PLoS ONE. 2016;11:e0158376.

480. Lipshultz SE, Anderson LM, Miller TL, Genschenson M, Stevenson KE, Neuberg DS, Franco VI, LiBotti DE, Silverman LB, Vrooom LM, et al. Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016;122:946–53.

481. Yadav N, Kumar S, Marlowe T, Chaudhary AK, Kumar R, Wang J, O’Malley J, Boland PM, Jayanthi S, Kumar TK, et al. Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents. Cell Death Dis. 2015;6:e1969.

482. Bull VH, Rajalingam K, Thiede B. Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells. J Proteome Res. 2012;11:1609–20.

483. Cardoso CM, Custódio JB, Almeida LM, Moreno AJ. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol. 2001;176:145–52.

484. Torchilin VP. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu Rev Biomed Eng. 2002;4:197–204.

485. Kumar R, Han J, Lim H-J, Ren WX, Lim J-Y, Kim J-H, Kim JS. Mitochondrial induced and self-monitored intrinsic apoptosis by antitumor
theranostic prodru: in vivo imaging and precise cancer treatment. J Am Chem Soc. 2014;136:17836–43.

488. Cheng L, Wang X, Gong F, Liu T, Liu Z. 2D Nanomaterials for cancer theranostic applications. Adv Mater (Deerfield Beach, Fla). 2020;32:e1902333.

489. Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y. Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 2014;53:12320–64.

490. Nie W, Wu G, Zhang J, Huang L-L, Li J, Liu Y, Liu Z, Pu K, et al. Responsive exosome nano-biocongruents for synergistic cancer therapy. Angew Chem Int Ed Engl. 2020;59:2018–22.

491. Guo X, Yang N, Ji W, Zhang H, Dong X, Zhou Z, Li L, Shen H-M, Yao SG, Huang W. Mito-bomb: targeting mitochondria for cancer therapy. Adv Mater. 2021;33:e2007778.

492. Fulda S, Galluzzi L, Kroemer G. Targeting mitochondria for cancer therapy. Nat Rev Drug Discovery. 2010;9:447–64.

493. Wang W, Liu J, Feng W, Du S, Ge R, Li J, Liu Y, Sun H, Zhang D, Zhang H, et al. Targeting mitochondria with Au-Ag@Polydopamine nanoparticles for papillary thyroid cancer therapy. Biomater Sci. 2019;7:1052–63.

494. Pathania D, Millard M, Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev. 2009;61:1250–75.

495. Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, Vasquez-Vivar J, Cheng C, Lopez M, Kalyanaraman B. Mitochondria-targeted triphenylphosphonium-based compounds: synthesis, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev. 2017;117:10043–120.

496. Chan MS, Liu LS, Leung HM, Lo PK. Cancer-cell-specific mitochondria-targeted drug delivery by dual-ligand-functionalized nanodiamonds circumventing drug resistance. ACS Appl Mater Interfaces. 2017;9:11780–9.

497. Wang H, Zhang F, Wen H, Shi W, Huang Q, Huang Y, Xie L, Ren J, Qin L, et al. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis. J Nanobiotechnol. 2020;18.

498. Cho H, Cho Y-Y, Shim MS, Lee JY, Lee HS, Kang HC. Mitochondria-targeted drug delivery in cancers. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165808.

499. Pfanner N, Warscheid B, Wiedemann N. Mitochondrial proteins: from bio genesis to functional networks. Nat Rev Mol Cell Biol. 2019;20:267–84.

500. Kreimendahl S, Schwichtenberg J, Günnewig K, Brandherm L, Rassow J. The selectivity filter of the mitochondrial protein import machinery. BMC Biol. 2020;18:156.

501. Bader MJ, Frazier AE, Gulbis JM, Ryan MT. Mitochondrial protein-import machinery: correlating structure with function. Trends Cell Biol. 2007;17:456–64.

502. Di Maio R, Barrett PJ, Hoffman EK, Barrett CW, Zhanvik A, Borah A, Hu X, McCoy J, Chu CT, Burton EA, et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci Transl Med. 2016;8:352ra78.

503. Segui-Real B, Stuart RA, Neupert W. Transport of proteins into the various subcompartments of mitochondria. FEBS Lett. 1992;313:2–7.

504. Eisenberg-Bord M, Schulderer M. Ground control to major TOM: mitochondria-nucleus communication. FEBS J. 2017;284:196–210.

505. Hartl FU, Neupert W. Protein sorting to mitochondria: evolution- ary conservations of folding and assembly. Science (New York, NY). 2001;292:490–8.

506. Yu H, Mehta A, Wang G, Hausworth WW, Chiodo V, Boye SL, Guy J. The selectivity filter of the mitochondrial protein import machinery. Oncogene. 2007;26:747–54.

507. Matissek KJ, Okal A, Mossalam M, Lim CS. Delivery of a monomeric p53 theranostic prodrug: in vivo imaging and precise cancer treatment. J Am Chem Soc. 2014;136:17836–43.

508. Cerrato CP, Pirisun M, Vlachos EN, Langel U. Novel cell-penetrating peptide targeting mitochondria. FASEB J. 2015;29:4589–99.

509. Cheng CJ, Saltzman WM. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials. 2011;32:6194–203.

510. Bai H, You Y, Yan H, Meng J, Yue X, Hou Z, Zou Y, Ma X, Sang G, Luo X. Antisense inhibition of gene expression and growth in gram-negative bacteria by cell-penetrating peptide conjugates of peptide nucleic acids targeted to rpoD gene. Biomaterials. 2012;33:659–67.

511. Liu BR, Liu J-S, Chen Y-J, Huang Y-W, Lee H-J. Delivery of nucleic acids, proteins, and nanoparticles by arginine-rich cell-penetrating peptides in rotifers. Mar Biotechnol (NY). 2013;15:584–95.

512. Aguilera TA, Olson ES, Timmers MM, Jiang T, Tisen RY. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integrative Biol. 2009;1:371–81.

513. Bode SA, Wallbrcher R, Brock R, van Hest JCM, Lowik DWPM. Activation of cell-penetrating peptides by disulfide bridge formation of truncated precursors. Chem Commun (Camb). 2014;50:415–7.

514. Hansen MB, van Gaal E, Minter I, Storm G, van Hest JCM, Lowik DWPM. Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes. J Controlled Release. 2012;164:87–94.

515. Kardani K, Milani H, Shabani S, Bolhassani A. Cell penetrating peptides: the potent multi-cargo intracellular carriers. Expert Opinion Drug Delivery. 2019;12:1627–28.

516. Khan MM, Filpicznak N, Torchilin VP. Cell penetrating peptides: a versatile vector for co-delivery of drug and genes in cancer. J Controlled Release. 2021;330:1220–8.

517. Park SE, Sajid MI, Parang K, Tiwari RK. Cyclic cell-penetrating peptides as efficient intracellular drug delivery tools. Mol Pharm. 2019;16:3727–43.

518. Wu L, Li J, Wang H, Liu C-B. Mitochondrial-targeted penetrating peptide delivery for cancer therapy. Expert Opin Drug Deliv. 2018;15:951–64.

519. Chen W, Jin M-J, Gao G-Z, Wang L-P, Piao H-F. Preparation and in vitro evaluation of pH-sensitive TAT peptide conjugated micelles. Yao Xue Xue Bao. 2011;46:599–604.

520. Liu D, Angelova A, Liu J, Garamus VM, Angelov B, Zhang X, Li Y, Feger G, Li N, Zou A. Self-assembly of mitochondria-specific peptide amphiphiles amplifying lung cancer cell death through targeting the VXAC1-hexokinase-II complex. J Mater Chem B. 2019;7:47406–16.

521. Woldeadadi AD, Vogel MC, Rabeh WM, Magzoub M. Hexokinase II-derived cell-penetrating peptide targets mitochondria and triggers apoptosis in cancer cells. FASEB J. 2017;31:12688–94.

522. Johnson LV, Walsh ML, Bockus BJ, Chen LB. Monitoring of relative mitochondrial membrane potential in living cells by fluorescence microscopy. J Cell Biol. 1981;88:526–35.

523. Wallace DC. Mitochondria and cancer. Nat Rev Cancer. 2012;12:685–98.

524. Samudio I, Feigl M, Andreuff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Can Res. 2009;69:2163–6.

525. Qian K, Chen H, Qu C, Qi J, Du B, Ko T, Xiang Z, Kandawa-Schulz M, Wang Y, Cheng Z. Mitochondria-targeted delocalized lipophilic cation complexed with human serum albumin for tumor cell imaging and treatment. Nanomol Nanotechnol Biomol Med. 2020;23:102087.

526. Jiang Z, Liu H, He H, Yadava N, Chambers JJ, Thayumanavan S. Anionic polymers promote mitochondrial targeting of delocalized lipophilic cations. Bioconjug Chem. 2020;31:1344–53.

527. Kelley SQ, Stewart KM, Mourtada R. Development of novel peptides for mitochondrial drug delivery: amino acids featuring delocalized lipophilic cations. Pharm Res. 2011;28:2808–19.

528. Modica-Napolitano JS, Aprille JR. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev. 2001;49:63–70.

529. Bernal SD, Lampidis TJ, Summerhayes IC, Chen LB. Rhodamine-123 selectively reduces clonal growth of carcinoma cells in vitro. Science (New York, NY). 1982;218:1117–9.

530. Lampidis TJ, Bernal SD, Summerhayes IC, Chen LB. Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Can Res. 1985;45:716–20.

531. Murphy MP. Selective targeting of bioactive compounds to mitochondria. Trends Biotechnol. 1997;15:326–30.
536. Boddapati SV, Tongcharoensirikul P, Hanson RN, D’Souza GGM, Torchilin VP, Weissig V. Mitochondrotoxic Liposomes. J Liposome Res. 2005;15:49–58.

537. Boddapati SV, D’Souza GGM, Erdogan S, Torchilin VP, Weissig V. Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett. 2008;8:2559–63.

538. Asin-Cayuela J, Manas A-RR, James AM, Smith RAJ, Murphy MP. Fine-tuning the hydrophobicity of a mitochondria-targeted antioxidant. FEBS Lett. 2004;571.

539. Hardy M, Pouilhès F, Rizzato E, Rockenbauer A, Suthamadavan S, et al. Mitochondria-targeted spin traps: synthesis, superoxide spin trapping, and mitochondrial uptake. Chem Res Toxicol. 2014;27:115–65.

540. Biswas S, D ’ od wav alk NS, Deshpande PP, Torchilin VP. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release. 2012;159:393–402.

541. Zhou J, Zhao W-Y, Ma X, Ju R-J, Li X-Y, Ma X, Ju R-J, Zhang C-X, Lu W-L. The antitumor efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials. 2013;34:3626–38.

542. Sun W, Wang J, Song K, Chen LB. Anticarcinoma activity of a novel drug, 3-ethyl-3’-methyl-thiatelluracarbocyanine iodide (Tel), a tellurium-containing cyanine targeted at mitochondria. Clin Cancer Res. 1996;2:1335–40.

543. Pan Y, Zhao S, Chen F. The potential value of dequalinium chloride in the treatment of cancer: focus on malignant glioma. Exp Clin Pharmacol Physiol. 2021;48:445–54.

544. Bailly C. Medicinal applications and molecular targets of dequalinium chloride. Biochem Pharmacol. 2021;186:114467.

545. Wang X-X, Ma X, Ju R-J, Zhang C-X, Lu W-L. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-diestearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials. 2011;32:5673–87.

546. Wang H, Yin H, Yan F, Sun M, Du L, Peng W, Li Q, Feng Y, Zhou Y. Folate-mediated mitochondrial targeting with doxorubicin-polysaccharide nanoparticles overcomes multidrug resistance. Oncotarget. 2015;6:28157–67.

547. Lv W, Guo J, Ping Q, Song Y, Li J. Comparative pharmacokinetics of brevicapecine liposomes in dogs, rabbits and rats. Int J Pharm. 2008;359:118–22.

548. Chen C-L, Chang S-F, Lee D, Yang J-Y, Lee C-H, Chen Y-S, Li S-J, Liao J. Bioavailability effect of methylprednisolone by polymeric micelles. Pharm Res. 2008;25:39–47.

549. Mu L-M, Ju R-J, Liu R, Bu Y-Z, Zhang J-Y, Li X-Q, Zeng F, Lu W-L. Dual-functional drug nanoparticles in treatment of resistant cancers. Adv Drug Deliv Rev. 2017;115:45–56.

550. Francesko A, Petkova P, Tzanos T. Hydrogel dressings for advanced wound management. Curr Med Chem. 2018;25:782–97.

551. Huang H-J, Tsai Y-L, Lin S-H, Hsu S-H. Smart polymers for cell therapy and precision medicine. J Biomed Sci. 2019;26:73.

552. Farouk F, Sharma R. Chemical structure modifications and nano-technology applications for improving ADMET-Tox properties, a review. Arch Pharm. 2019;352:e1800213.

553. Lim D, Jung WC, Jeong J-H, Song M. Targeted delivery of the mitochondrial target domain of nova to tumor tissue via synthetic secretion system in E. coli. Front Bioeng Biotechnol. 2020;8:840.

554. Luo X, Gong X, Su L, Lin H, Yang Z, Yan X, Gao J. Activatable mitochondria-targeting organoarsenic prodrugs for bioenergetic cancer therapy. Angew Chem Int Ed Engl. 2021;60:1403–10.

555. Cheng G, Hardy M, Topchyan P, Zander R, Volberding P, Cui W, Kalyanaraman B. Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone. Sci Rep. 2020;10:17872.

556. Mu L-M, Ju R-J, Li X, Liu H, Wang PG, Wang C, Wang J, Luo W, Xie S. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance. Bioorg Chem. 2020;99:103768.

557. Xing Y, Jiang Z, Akakuuru OU, He Y, Li A, Li J, Wu A. Mitochondria-targeting zeolitic imidazole frameworks to overcome platinum-resistant ovarian cancer. Colloids Surf B Biointerfaces. 2020;189:110837.

558. Chen L, Wang C, Feng L, Yang K, Liu Z. Functional nanomaterials for phototherapies of cancer. Chem Rev. 2014;114:10869–939.

559. Karimi M, Sahandi Zangabad P, Baghaee-Ravar S, Ghazadeh M, Mirshekari H, Hamblin MR. Smart nanostructures for cargo delivery: uncaging and activating by light. J Am Chem Soc. 2017;139:4584–610.

560. Zhang L, Wang D, Yang K, Sheng D, Tan B, Wang Z, Pan H, Yi H, Zhong Y, Lin H, et al. Mitochondria-targeted artificial “Nano-RBCs” for amplified synergistic cancer phototherapy by a single NIR irradiation. Adv Sci (Weinheim, Baden-Württemberg, Germany). 2018;5:1800049.

561. Smith AM, Mancini MC, Nie S. Bioimaging: second window for in vivo imaging. Nat Nanotechnol. 2009;4:710–11.

562. Hemmer E, Acosta-Mora P, Méndez-Ramos J, Fischer S. Optical nanoprobes for biomedical applications: shining a light on upconverting and near-infrared emitting nanoparticles for imaging, thermal sensing, and photodynamic therapy. J Mater Chem B. 2017;5:4365–92.

563. Sun W, Lu Y, Gu Z. Advances in anticancer protein delivery using micro-/nanoparticles. Particle Particle Synt Charact. 2014;41:1204–22.

564. Li X, Lovell JF, Yoon J, Chen X. Clinical development and potential of photothermal and photodynamic therapies for cancer. Nat Rev Clin Oncol. 2020;17:657–74.

565. Chen S, Lei Q, Qu W-X, Liu L-H, Zheng D-W, Fan J-X, Rong L, Sun Y-X, Zhang X-Z. Mitochondria-targeting “Nanoheater” for enhanced photothermal chemotherapy. Biomaterials. 2017;117.

566. Tao W, Zhu X, Yu X, Zeng Q, Xiang Z, Ji X, Wang X, Shi J, Zhang H, et al. Black phosphorus nanosheets as a robust delivery platform for cancer theranostics. Adv Mater (Deerfield Beach, Fla). 2017;29.

567. Jung HS, Verweij P, Sharma A, Shin J, Sessler JL, Kim JS. Organic molecule-based photothermal agents: an expanding photothermal therapy universe. Chem Soc Rev. 2018;47:2280–97.

568. Chen S, Zhao X, Chen J, Chen J, Kuznetsova L, Wong SS, Ojima J. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjugate Chem. 2010;21:979–87.

569. Marrache S, Dhar S. The energy blocker inside the power house: mitochondria targeted delivery of 3-bromopyruvate. Chem Sci. 2015;6:1832–45.

570. Kang JH, Ko YT. Dual-selective photodynamic therapy with a mitochondria-targeted photosensitizer and fiber optic cannula for malignant brain tumors. Biomater Sci. 2019;7:2812–25.

571. Nagashima C. Multiple surgery of recurrent intramedullary spinal cord tumors. Nervenklinik, Karlsruhe, Germany. 2018;5:1800049.

572. Cerman E, Cekic O. Clinical use of photodynamic therapy in ocular tumors. Surv Ophthalmol. 2015;60:557–74.

573. Ming H, Li B, Tian H, Zhou L, Jiang J, Zhang T, Qiao L, Wu P, Nice EC, Zhang W, He W, Huang C, Zhang H. A minimalistic and robust chemo-photothermal nanoplatform capable of augmenting autophagy-modulated immune response against breast cancer. Mater Today Bio. 2022;15:100289.

574. Hou H, Huang X, Wei G, Xu F, Wang Y, Zhou S. Fenton reaction-assisted photodynamic therapy for cancer with multifunctional magnetic nanoparticles. ACS Appl Mater Interfaces. 2019;11:29579–92.

575. Zeng L, Pan Y, Tian Y, Wang X, Ren W, Wang S, Lu G, Wu A. Doxorubicin-loaded NaYF4:Yb/Tm:TeO2 inorganic photosensitizers for NIR-triggered photodynamic therapy and enhanced chemotherapy in drug-resistant breast cancers. Biomaterials. 2015;57.

576. Zhang C, Bu W, Ni D, Zhang S, Li Q, Yao Z, Zhang J, Yao H, Wang Z, Shi J. Synthesis of iron nanometallic glasses and their application in cancer therapy by a localized fenton reaction. Angew Chem Int Ed Engl. 2016;55:2101–6.

577. Sharker SM, Kim SM, Kim SH, In I, Lee H, Park SY. Target delivery of 3-bromopyruvate. Colloids Surf B Biointerfaces. 2020;189:110837.

578. Sharker SM, Kim SM, Kim SH, In I, Lee H, Park SY. Target delivery of 3-bromopyruvate. Colloids Surf B Biointerfaces. 2020;189:110837.
579. Yang G-G, Pan Z-Y, Zhang D-Y, Cao Q, Ji L-N, Mao Z-W. Precisely assembled nanoparticles against cisplatin resistance via cancer-specific targeting of mitochondria and imaging-guided chemo-photothermal therapy. ACS Appl Mater Interfaces. 2020;12:44444–55.

580. Cheng H, Zheng R-R, Fan G-L, Fan J-H, Zhao L-P, Jiang X-Y, Yang B, Yu X-Y, Li S-Y, Zhang X-Z. Mitochondria and plasma membrane dual-targeted chimeric peptide for single-agent synergistic photodynamic therapy. Biomaterials. 2019;188.

581. Liu J, Liang H, Li M, Luo Z, Zhang J, Guo X, Cai K. Tumor acidity activating multifunctional nanoplatform for NIR-mediated multiple enhanced photodynamic and photothermal tumor therapy. Biomaterials. 2018;157:107–24.

582. Chen H, Wang Y, Yao Q, Yao S, Wang H, Tan N. Sequential delivery of cyclopeptide RA-V and doxorubicin for combination therapy on resistant tumor and monitoring of cytochrome c release. Theranostics. 2017;7:3781–93.

583. Xiao Q, Dong X, Yang F, Zhou S, Xiang M, Gao L. Engineered cell-penetrating peptides for mitochondrion-targeted drug delivery in cancer therapy. Chem. (Weinheim an der Bergstrasse, Germany). 2012;127:14721–9.

584. Shi J-F, Sun M-G, Li X-Y, Zhao J, Yu R-J, Mu L-M, Yan Y, Li X-T, Zeng F, Liu W-L. A combination of targeted sunitinib liposomes and targeted vinorelbine liposomes for treating invasive breast cancer. J Biomed Nanotechnol. 2015;11:1568–82.

585. He L, Zhao M-M, Pan Z-Y, Wang K-N, Zhao Z-L, Li Y-F, Mao Z-W. A mitochondria-targeted iridium(ii)-based photoacid generator induces dual-mode photodynamic damage within cancer cells. Chem Commun (Camb). 2019;55:10472–5.

586. Song X-D, Kong X, He S-F, Chen J-X, Sun J, Chen B-B, Zhao J-H, Mao Z-W. Cyclometalated iridium(ii)-guanidinium complexes as mitochondria-targeted anticancer agents. Eur J Med Chem. 2017;138:246–54.

587. Cheng J, Yi Y. Mitochondria-targeting nanomedicine self-assembled from GSH-responsive paclitaxel-ss-berberine conjugate for synergistic cancer treatment with enhanced cytotoxicity. J Control Release. 2020;318:38–49.

588. Yan J, Chen J, Zhang N, Yang Y, Zhuo W, Li H, He B. Mitochondria-targeted tetra-hedral DNA nanoparticles for doxorubicin delivery and enhancement of apoptosis. J Mater Chem B. 2020;8:492–503.

589. Orienti I, Salvati V, Setti G, Zucchietti M, Bongiorno-Borbone L, Peschiaroli A, Zeng J-Y, Zou M-Z, Zhang M, Wang X-S, Zeng X, Cong H, Zhang X-Z. Mitochondria-targeted and ultrasound-activated nanodroplets for enhanced glucose uptake and photothermal tumor therapy. Biomaterials. 2018;157:107–24.

590. Craven L, Tuppen HA, Greggains GD, Harbottle SJ, Murphy JL, Cree LM, Murdock AP, Chinnery PF, Taylor RW, Lightowlers RN, et al. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature. 2010;461:367–72.

591. Craven L, Tuppen HA, Greggains GD, Harbottle SJ, Murphy JL, Cree LM, Murdock AP, Chinnery PF, Taylor RW, Lightowlers RN, et al. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature. 2010;461:367–72.

592. Hylopi LA, Blakeley P, Craven L, Richardson J, Fogarty NME, Fragouli E, Lamb J, Blakeley P, Chinnery PF, et al. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. J Am Chem Soc. 2018;140:1215–8.

593. Tachibana M, Sparman M, Sritanaudomchai H, Ma H, Clepper L, Woodworth SG, Boulammar N, et al. Chimeric peptide for single-agent synergistic photodynamic therapy. Cancer Discov. 2017;7:3781–93.

594. Vazquez F, Lim J-H, Chen H, Bhalla K, Gimun G, Pierce K, Clish CB, Granter SR, Wendlund HR, Spiegelman BM, et al. PGc1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 2013;23:287–301.

595. Henkenius K, Greene BH, Backhausen C, Hartmann R, Marken K, Kaiser T, Rehberger M, Metzelder SK, Parak WJ, Neubauer A, et al. Maintenance of cellular respiration indicates drug resistance in acute myeloid leukemia. Leuk Res. 2017;62:56–63.

596. Farge T, Saland E, de Toni F, Aroua N, Hossein M, Perry R, Bosc C, Sugita M, Stuani L, Fraisse M, et al. Chemotherapy-resistant human acute myeloid leukemia cells are not enriched for leukemic stem cells but require oxidative metabolism. Cancer Discov. 2017;7:716–35.

597. Zhan X-K, Li J-H, Zhang S, Xing P-Y, Xia MI-F. Betalamic acid exerts potent anti-tumor effects on paclitaxel-resistant human lung carcinoma cells (H460) via G2/M phase cell cycle arrest and induction of mitochondrial apoptosis. Oncol Lett. 2018;16:3628–34.

598. van Ginkel PR, Sareen D, Subramanian L, Walker Q, Darjatmoko SR, Lindstrom MJ, Kulkarni A, Albert DM, Polans AS. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res. 2007;13:5162–9.

599. Cheng G, Zhang Q, Pan J, Lee Y, Ouari O, Hardy M, Zielonka M, Myers CR, Zielonka J, Web K, et al. Targeting ionodamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat Commun. 2019;10:2205.

600. Chen W, Duyang J, Chen M, Zhang K, Sheng J, Liu J, Han Y, Wang L, Liu J, et al. Black phosphorus nanosheet-based drug delivery system for synergetic photodynamic/photothermal/chemotherapy of cancer. Adv Mater (Deerfield Beach, Fla). 2017;29.

601. Nam J, Son S, Ochly LL, Kaur R, Schwedemman A, Moon JH. Chemo-photothermal therapy combination elicits anti-tumor immunity against advanced metastatic cancer. Nat Commun. 2018;9:1074.

602. Lu K, He C, Guo N, Chan C, N K, Lan G, Tang H, Pelzarii C, Fu-YX, Spitto MT, et al. Low-dose X-ray radiotherapy-photodynamic therapy via nanoscale metal-organic frameworks enhances checkpoint blockade immuno-therapy. Nat Biom Eng. 2018;6:600–10.

603. Zeng J-Y, Zou M-Z, Zhang M, Wang X-S, Zeng X, Cong H, Zhang X-Z. n-Extended benzophenone-based metal-organic framework for inhibition of tumor metastasis. ACS Nano. 2018;12:4630–40.

604. Zhang L, Yi H, Song J, Huang J, Yang K, Tan B, Wang D, Yang N, Wang Z, Li X. Mitochondria-targeted and ultrasound-activated nanodroplets for enhanced deep-penetration sonodynamic cancer therapy. ACS Appl Mater Interfaces. 2019;11:19355–66.

605. Cardoso AM, Morais CM, Cruz AR, Cardoso AL, Silva SG, do Vale ML, Marques EF, Pedrero de Lima MC, Jurado AS. Gemini surfactants mediate efficient mitochondrial gene delivery and expression. Mol Pharmaceutics. 2015;12:716–30.

606. Bae Y, Jung MK, Song S, Green ES, Lee S, Park H-S, Jeong SH, Han J, Mun JY, Ko KS, et al. Functional nanosome for enhanced mitochondria-targeted gene delivery and expression. Mitochondrion. 2017;37:27–40.

607. Coutinho E, Batista C, Sousa F, Queiroz J, Costa D. Mitochondrial gene therapy: advances in mitochondrial gene cloning, plasmid production, and nanosystems targeted to mitochondria. Mol Pharm. 2017;14:626–38.

608. He T, Qin X, Jiang C, Jiang D, Lei S, Lin J, Zhuo W-G, Qu J, Huang P. Tumor pH-responsive metabolizable-phase manganese sulfide nanotheranostics for traceable hydrogen sulfide gas therapy primed chemodynamic therapy. Theranostics. 2020;10:2453–62.

609. Motterlin R, Otterbein LE. The therapeutic potential of carbon monoxide. Nat Rev Drug Discover. 2010;9:728–43.

610. Kim S, Tachikawa T, Fujita T, Majima T. Far-red fluorescence probe for monitoring singlet oxygen during photodynamic therapy. J Am Chem Soc. 2014;136:1707–15.
618. Hu P, Wu T, Fan W, Chen L, Liu Y, Ni D, Bu W, Shi J. Near infrared-assisted Fenton reaction for tumor-specific and mitochondrial DNA-targeted photochemotherapy. Biomaterials. 2017;141:86–95.

619. Yang Z, Wang J, Liu S, Li X, Miao L, Yang B, Zhang C, He J, Ai S, Guan W. Defeating relapsed and refractory malignancies through a nano-enabled mitochondria-mediated respiratory inhibition and damage pathway. Biomaterials. 2020;229:119580.

620. Zeng F, Qin H, Liu L, Chang H, Chen Q, Wu L, Zhang L, Wu Z, Xing D. Photoacoustic-immune therapy with a multi-purpose black phosphorus-based nanoparticle. Nano Res. 2020.

621. Bosic C, Selak MA, Sarry J-E. Resistance is futile: targeting mitochondrial energetics and metabolism to overcome drug resistance in cancer treatment. Cell Metab. 2017;26:705–7.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.